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Medication adherence is defined as the extent to which patients take medications 
according to agreed recommendations from a health care provider. Correspondingly, 
medication non-adherence is the failure to take medications according to a prescribed 
medication regimen.  Considered one of the greatest challenges to the successful 
management of people with chronic conditions in the community setting, patients who 
are non-adherent to medications have higher risks for hospitalization and even death 
compared to patients who take medications as prescribed. According to a report in 2008, 
the costs due to non-adherence in the United States (US) was estimated to be between 
US$100 billion to US$310 billion per year; however, these numbers are based on general 
assumptions and rigorous estimates are not available in the US or Canada. Despite years 
of research, major gaps remain in our understanding of the causes of non-adherence. 
Studies often focus on patient characteristics and patient behaviour. Although some of 
these factors are influential, they typically only explain a small fraction of the variance in 
models predicting non-adherence. Prescribing physicians have been identified as having a 
strong influence on their patient’s adherence to medications; however, their impact has 
never been comprehensively incorporated into population-based models to help explain 
the residual variance.  
Purpose and research approach: 
The purpose of this research was to examine the impact of physicians on 
population-based models of medication adherence. Three retrospective cohort studies 
were conducted using population-based, administrative databases from Saskatchewan, 
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Canada. The study population consisted of new statin users (no statin claims in the 
previous five year) between 2012 and 2017. Statin medication was the focus in these 
studies because they are prescribed for chronic treatment only, they had no therapeutic 
equivalent during the period of study, they are prescribed to a large percentage of the 
population, and they are associated with reduced morbidity and mortality from 
atherosclerotic cardiovascular disease. Each study focused on different aspects of the 
physician’s potential impact on the outcome of optimal medication adherence to statins 
defined as proportion of days covered (PDC) of at least 80%. Study 1 measured the 
impact of continuity of care (COC) provided by physician prescribers on optimal 
adherence; study 2 focused on the impact of demographic characteristics of physicians on 
optimal adherence; and study 3 measured the overall effect of physicians on the outcome 
of optimal adherence.   
Study 1 – The impact of physician continuity of care on medication adherence 
The first study investigated continuity of care (COC), a factor related to physician 
practice that is associated with medication adherence and is commonly used as a baseline 
explanatory variable in population-based studies. COC is typically represented by the 
usual provider continuity index (UPCI), which is calculated exclusively from the number 
of outpatient physician visits. However, the number of outpatient visits only represents 
one aspect of COC. Our aim was to improve the measurement of COC by integrating 
information on physician services and pharmacy claims (i.e., medication dispensing) data. 
Our new “integrated COC” definition required patients to have one physician who 
satisfied all three criteria: a) the most frequently visited general practitioner physician 
(i.e., usual care provider); b) the statin prescriber; and c) provider of a complete medical 
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examination within the past year.  Logistic regression models were constructed with each 
measure of COC (high UPCI index or integrated COC) on the outcome of optimal statin 
adherence (PDC ≥80%). Predictive performance of the two models was compared using 
the DeLong test. In a cohort of 55,144 new statin users, the integrated COC measure had 
a stronger association with optimal adherence [adjusted odds ratio (aOR) =1.56, 95% 
confidence interval (CI) 1.50 to 1.63] than UPCI (aOR = 1.23, 95% CI 1.19 to 1.28), and 
produced greater prediction accuracy of the multivariable model (DeLong test, p<0.0001). 
The results suggest that physician service and pharmacy claim data should be adopted in 
COC measures for population-based adherence models because of greater predictive 
performance in models predicting optimal adherence to statin. 
Study 2 – Physician demographic factors and medication adherence 
The second study examined the impact of age or sex concordance (i.e., same age 
range or same sex) between physicians and patients on optimal adherence to statin 
medications. We hypothesized that age or sex concordance between physicians and 
patients would result in higher medication adherence through improved communication 
and trust compared to non-concordant pairs. Multivariable logistic regression models by 
generalized estimating equations were applied to examine odds of optimal adherence 
associated with age and/or sex concordance. Among 51,874 pairs of new statin users and 
1,562 prescribers, no influence of age concordance on the odds of optimal adherence 
could be detected (aOR = 1.02, 95%CI 0.97 to 1.07). The association between sex 
concordance and optimal statin adherence was stronger but failed to reach statistical 
significance by a very small margin (aOR=1.05, 95%CI 1.00 to 1.11). It suggested that 
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the potential for an important influence of sex concordance remains and should be 
investigated in other health care settings.    
Study 3 – The overall impact of physicians on medication non-adherence 
The third study aimed to quantify the overall impact of physicians on optimal 
statin adherence. We identified the prescriber for each new statin user and measured each 
patient’s adherence one-year after the initial dispensation. The overall physician impact 
on optimal medication adherence (i.e., PDC >= 80%) was estimated from the intraclass 
correlation coefficient (ICC) derived from a random intercept model controlled by 
numerous patient-level variables (e.g., sex, residence, income, etc.). We also examined 
the impact of unmeasured physician factors or latent effects based on the ICC of a 
random intercept model controlled by both patient variables and physician-level factors 
(e.g., country of medical training, remuneration type, statin patient count, etc.).  Finally, 
we estimated the impact of specific physician-level factors [sex, country of medical 
training, years in practice, remuneration type, number of patients, and number of patients 
taking a statin (statin patient count)]. Unadjusted odds ratios (uOR) for each factor were 
generated from logistic regression models; adjusted odds ratios (aORs) were obtained 
from non-linear mixed-effects logistic regression models adjusted by patient-level 
variables. Our results were derived from 51,874 new statin users. Addition of the 
physician effect to a model consisting of multiple patient-level factors only explained an 
additional 6.4% of the observed variance in adherence between patients, of which 
physician-level factors had a minimal contribution. The vast majority of the overall 
physician impact (5.2% out of a possible 6.4%) was attributed to a “latent effect” of the 
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prescriber. The results suggest that the overall impact of prescribers on optimal statin 
adherence appears to be very limited.  
Future research 
Research on the influence of physicians should continue with different types of 
medications and conditions. Also, specific factors such as COC, type of physician 
remuneration, sex concordance, and country of medical education require further study to 
help understand the complex role of physicians and potential new targets for improving 
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 Introduction Chapter 1
1.1 Medication use in Canada  
Prescription medications are used very frequently in Canada. In 2019, total health 
care spending in Canada was 11.5% of gross domestic product (GDP), or $265.5 billion, 
of which medications were the second highest contributor ($40.4 billion, 15.2%) after 
hospital services ($70.1 billion, 26.4%).
1
 Almost half of all spending on medications in 
Canada comes directly from provincial/territorial governments (approximately $15.0 




Although medications contribute substantial costs to Canada’s health care system, 
their use can be associated with substantial downstream savings. Medications that treat 
chronic diseases can lower morbidity, mortality, and improve quality of life.
3
 Among 
patients with cardiovascular diseases, blood-pressure-lowering regimens and blood-
cholesterol-lowering agents can reduce risk for coronary events by 16% to 20%, stroke 
by 17% to 42%, total cardiovascular events by 11% to 30%, and death by 11% to 17%.
4-6
 
Among patients with type II diabetes, metformin has been associated with a reduction in 
the risk of myocardial infarction by 33%, and death by 24% to 33%.
7, 8
 Among patients 
diagnosed with depressive disorders, anti-depressants can prevent recurrence of 
symptoms for 0.5 to 5 years.
9, 10
 Anti-depressant agents are also effective in mitigating 
the impact of mental health on employment.
11
 Ultimately, appropriate medication use in 
the community can reduce the demand for expensive hospital care and costs due to loss 
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of productivity. Thus, managing chronic diseases in the community is a key strategy for 
sustainable health care in the future.  
1.2 Medication adherence 
Overview 
Medication adherence is defined as the extent to which patients take medications 
according to agreed recommendations from a health care provider.
3, 12
 Several terms have 
been used to describe this concept over the years including “concordance” and 
“compliance”.
13, 14
 The term “compliance” was criticized by some scholars because it 
ignores the importance of patient engagement.
15
 A more recent term that has been 
proposed is “medication concordance”. The term was thought to better reflect the 
patient’s participation in their own care.
15
 At present, the term “medication adherence” 




Conversely, medication non-adherence is the failure to take medications 
according to a prescribed medication regimen. It is generally classified into three types: 
primary non-adherence, poor execution, and non-persistence.
17
 Primary non-adherence 
refers to a situation where patients fail to initiate a prescribed medication.
17
 Poor 
execution is the failure to follow the recommended timing, dosage, and/or frequency of 
medication (e.g., skipping doses).
17
 Non-persistence refers to the premature 
discontinuation of a required medication.
17
 These patterns of non-adherence may 
represent distinct situations and likely have some unique causes. For example, an 
individual exhibiting non-persistence (i.e., quitting a medication altogether) is likely 
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influenced by unique factors compared to another individual exhibiting poor execution 
(i.e., skipping doses/taking irregularly).
17
 As a result, non-adherence has been associated 
with multiple possible determinants but no single factor has been shown to play a strong 
role.
3
   
The prevalence of medication non-adherence in Canada is concerning. In a study 
of Saskatchewan’s senior population (aged 65+), non-adherence was found in 40% of the 
patients receiving anti-depressant agents, 39% of those receiving oral blood-glucose-
lowering agents, 33% of those receiving blood-cholesterol-lowering agents, and 24% of 
those receiving blood-pressure-lowering agents.
18
 Patients exhibiting non-adherence have 
poor outcomes compared to those who take medications regularly. For example, patients 
exhibiting non-adherence to antihypertensive medications are half as likely to achieve 
target blood pressure levels.
19
 Similarly, low adherence to cholesterol-lowering 
medications is associated with a 25 to 27% increase low-density lipoproteins (LDL) 
levels and 26% higher risk of developing cerebrovascular events.
20
 Among diabetic 
patients, those exhibiting non-adherence to oral blood-glucose-lowering medications are 
58% more likely to be hospitalized, and 81% more likely to die.
21
 Medication non-
adherence is also associated with higher health care costs, primarily resulting from the 
occurrence of avoidable hospitalizations.
12
 A study in 2008 reported that, in the United 
States (US), the costs due to non-adherence are assumed to be between US$100 billion to 
US$310 billion per year; however, these numbers are based on general assumptions and 
rigorous estimates are not available in the US or Canada.
22
   
The staggering estimates regarding the cost of non-adherence has drawn 
significant attention over the years. The problem appears so great that some have 
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suggested solutions to non-adherence may be more important than the discovery of new 
therapeutic agents.
23, 24
 As a result, research about medication adherence is a main focus 
of pharmacoepidemiology because of its impact at the population level. It is important to 
identify drivers behind medication non-adherence at the population level to help guide 
strategies to mitigate its health and economic consequences.  
Measures of medication adherence 
Research into medication adherence has many challenges depending on the 
setting and patient population. One of the challenges facing all studies about adherence is 
accurate measurement. Medication adherence can be measured in various ways.
12, 14
 It is 
possible to directly measure adherence through biochemical testing of drug levels. 
However, this approach is costly and would be difficult to carry out routinely and in large 
populations.
12, 14
 Indirect methods of adherence measurement include subjective 
ratings/surveys and objective records of medication administration.
3, 23
  
Subjective records include patient diaries or self-reported surveys.
23
 Self-report 
adherence measures are disadvantaged by imprecision and susceptibility to bias.
25
 In a 
review by Conn and colleagues, studies using self-report measures exhibited significantly 
higher heterogeneity as opposed to studies not using self-report measures, with a 
heterogeneity statistic of 4.208 (p = 0.04). The authors argued that such heterogeneity 
indicated the presence of bias.
26
 Similar findings were reported by other researchers; 
subjective records were associated with recall bias or social stigma.
16, 24
  
Objective measures include pill counting, electronic pill bottles, and algorithms to 
calculate adherence levels (e.g., proportion of days covered, which will be articulated in 
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the following section) based on electronic pharmacy data (i.e., medication 
dispensations).
3, 12, 14
 Pill counting records the number of pills returned by patients to 
estimate the number of non-adherent days. Pill counting measures have also been 
criticized for the risk of inaccurate estimation of adherence. 
27, 28
 Studies suggest that pill 
counting overestimates adherence.
27, 28
 Electronic pill bottles typically involve sensors 
that record every time the medication container is opened. Thus, every record represents 
a “pill-taking event”. These devices appear to be very precise in measuring adherence. 
29
 
However, they are costly and difficult to implement in large populations.
29
 Also, they are 
prone to Hawthorne effects (i.e., patients tend to behave adherent to medication as they 
know that they are being watched), and the adherence level can be overestimated.
30
 
Among all available methods, analyses of electronic pharmacy data have multiple 
advantages.
31, 32
 First, electronic pharmacy data are usually population-based.
33
 
Population-based data can provide high statistical power to detect even small effects due 
to the large number of observations.
33
 It contains data going back decades, enabling 
longitudinal research of trend and temporal relationships, and improves generalizability 
of results.
33
 Electronic pharmacy data is often managed by government or private 
insurance companies, thus, quality of data is typically high due to standardization and 
regular validation.
32
 These data contain information on the medications dispensed (e.g., 
date, strength, and quantities) and also capture a large number of variables including 
prescriber, social-demographic information, and cost. 
32, 33
 Another major advantage of 
electronic pharmacy data is the collection of medication use in real-world settings. As 
such, they are not prone to recall bias or Hawthorne effects.
32, 33
Finally, electronic 
pharmacy data can be linked to other health administrative databases such as physician 
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services, hospitalization records, or vital statistics to increase the availability of 
covariates (e.g., patient and physician characteristics) that can be used to characterize 
variation in adherence outcomes.
31-35
 As such, electronic pharmacy data are considered as 
one of the best sources for measuring medication adherence.
32
 
Saskatchewan is home to world-renowned administrative databases that have 
been used frequently to study medication adherence.
32
 The databases include a population 
registry, electronic pharmacy claims (for dispensations of prescription medications), 
hospital services, emergency services, physician claims, physician registry, and more.
32
 
The data is complete by covering all segments of the population in the province. The 
annual turnover of the registered population is lower than 5%, which provides a stable 
population for follow up.
32
 The major databases in Saskatchewan can be traced back for 
decades.
32, 36
 The pharmacy prescription claims file and the hospital claims file follow the 




 The common methods of measuring medication adherence from electronic 
pharmacy data include medication possession ratio (MPR),
38, 39
 continuous measure of 
medication acquisition (CMA),
39





estimates proportion of days’ supplied within a specified observation period.
38
 The 
advantage of MPR is its ease of calculation.
43
 However, the algorithm of MPR is not 
standardized. Hess and colleagues reported that there were at least four different 
published measures under the term “MPR”, which may cause confusion when comparing 
adherence across studies.
38, 43
 Use of days supply can be a problem as overlapping 
periods are not adjusted.
41
 As a result, MPR values can exceed 100% and the average 
7 
 
MPR across a population can be overestimated.
43
 If MPR is not truncated at 100%, the 
report on average MPR across patients can be overestimated.
43
 Also, when the 
denominator is measured between the first and last dispensations, it may bring multiple 
problems: 1) MPR cannot be calculated for those who had one dispensation; 2) The 
estimation on adherence can be imprecise if data is not available to trace back to the very 
first dispensation; 3) The ratios cannot be directly compared across patients as the length 
of observation is different; 4) Discontinuation of medications is not captured since 
observation ceases on the last dispensation.
43
 CMA is identical in measure of 
adherence,
38
 and shares the same problems as MPR has.
39
  




 PDC requires 
the number of days supply to be determined for every medication claim (or dispensation 
from the pharmacy). The days supply allows an estimate of when the next medication 
refill will be needed. For example, a medication claim of 60 tablets corresponds to 30 
days supplied for medications taken twice daily (i.e., two tablets per day). The PDC uses 
the total number of days supply divided by the number of days observed producing a 
percentage that is equated to an individual’s adherence during that time. For example, a 
patient who received 50 days supplied of medication during 100 days of observation is 
considered to have an adherence level of 50% (i.e., PDC = 50%).    
PDC is considered a precise algorithm to evaluate medication availability.
40-43
 
However, several modifications are often applied. First, accumulated supplies from 
previous dispensations, and days in hospital should be considered in the measurement of 
PDC.
40
 Second, although a common practice to define optimal adherence at PDC >=80%, 





 Third, prevalent users should be analyzed separately from incident users for the 
following reasons: 1) for prevalent users, the date of first fill cannot be identified, which 
undermines the precision of adherence calculation; 2) studies often showed high 
occurrence of discontinuation during the first year of therapy, suggesting that a mixed 
population of prevalent and incident users may confound the results.
40
 Finally, PDC does 
not detect medication discontinuations. Thus, low PDC values should be investigated for 
evidence of poor execution (i.e., skipping doses or late refills) versus non-persistence (i.e., 
complete medication discontinuation).   
Determinants of adherence 
Using a clinically-oriented framework, determinants of adherence can be classified 
into five categories: patient-related factors; socio-economic environmental factors; 
disease related factors; treatment related factors; and health care provider/system related 
factors.
22, 44, 45
 However, certain factors may fall into multiple categories, and have 
interactions with each other. For example, lack of education can be considered as a 
patient-related factor and a social-economic related factor. In addition, factors such as age, 
low income, and high treatment cost are often correlated, making it difficult to quantify 
their independent effects.  
A vast number of possible determinants of medication adherence have been 
examined in the literature. However, these factors virtually always have weak 
predictability in multivariable models.
46-48
 For example, in a study involving 444,418 
diabetic subjects, a prediction model was built with many patient-level factors that are 
typically available in administrative databases, such as demographic characteristics (e.g., 
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age, sex, and marital status), comorbidities (e.g., vascular disease, mental illness, and 
chronic lung or renal disorders), and regimen complexity. The study also included 
clinical factors such as disease severity, and laboratory test results. Despite the access to a 
wide array of clinical and administrative information, multivariate models only explained 
2.9% of the adherence variation observed in the study population.
47
  
It is unknown why such models have failed to predict non-adherence. In general, 
prediction models contain numerous variables representing widely accepted theoretical 
frameworks (including patient-level, disease, drug factors, etc.). A few factors have been 
consistently associated with adherence in multiple studies.
49
 For example, ethnic minority 
status, higher regimen complexity, higher co-payment, and higher medication cost are 
related to poorer adherence.
49
 In contrast, employment and income are related to better 
adherence.
49
 However, many well-recognized factors have failed to exhibit consistent 
effects on adherence. For example, studies often show heterogeneous associations 
between adherence and both sex and age.
49
 One possible reason for the variation is due to 
the use of different measures or different analytic methods.
49
 Mathes and colleagues 
reviewed seven systematic reviews on adherence of medications for a range of diseases, 
including chronic cancer pain, cancer, Parkinson’s disease, heart failure, rheumatoid 
arthritis.
49
 The authors found that adherence was higher in the middle age groups when 
measured as a categorical variable. 
49
 However, when measured as a continuous variable, 
the effect of age was insignificant or heterogeneious.
49
 Inconsistent results for a given 
factor can be due to differences in measurement or analytic approaches. Socioeconomic 
status (SES) is linked to education, economic status, and social support; therefore lower 





in a systematic review of 56 studies, Alsabbagh and colleagues observed very high 
heterogeneity in the reported associations between SES and non-adherence to blood-
pressure-lowering medications.
50
 The authors argued that a major source of the 
heterogeneity was different measures on SES.
50
 For example, seventeen studies used drug 
coverage or medication co-payment as proxies of SES, four used income-level,
50
 and 
three studies measured SES by social assistance benefits or income security benefits.
50
 
These measures reflected different aspects of SES, and could have different impact to 
medication adherence.
50
 Only seven of the reviewed studies tested more than one 
measure of SES.
50
 Indeed, measurement of adherence determinants is another possible 
contributor to the weak predictive performance of adherence models at the population 
level. One of the studies in this dissertation evaluated alternative measures for a 
commonly used covariate in adherence research, continuity of care.  
Behavioural theories and models related to medication adherence  
Since medication adherence has been strongly linked to knowledge, attitudes, and 
beliefs of patients, research in health behaviours has been commonly applied to the 
context of medication taking. The most widely studied theory of health behaviour is the 
health belief model (HBM).
51
 The term HBM is widely used, but indeed it refers to a 
behavioural theory. 
51
 Other commonly examined theories include the protection 
motivation theory, the theory of reasoned action, the theory of planned behaviour, and the 
social-cognitive theory and self-efficacy.
52
 The core of these theories is that human 
beings can change their behaviour through a dynamic social learning process.
52
 For 
example, HBM identifies three elements: a) perception of the health issue (e.g., 
susceptibility to a disease, severity of disease, and high risk towards an unfavorable 
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outcome); b) belief in treatment (e.g., perceived benefits of treatment, or perceived 
barriers of treatment); and c) a stimulus to facilitate participation in treatment (e.g., cues 
of action such as education and tools to help patients overcome barriers).
51
 These 
elements can determine patients’ self-efficacy (e.g., confidence in ability of coping with a 
particular disease), which leads to the expected outcomes.
52
  
Research on behaviour change could potentially guide interventions that are meant 
to increase an individual’s adherence to medications. Behaviour change has been 
commonly explained by the self-efficacy/social-cognitive theory, the relapse prevention 
model, and the transtheoretical or stages-of-change model.
52
 These theories focus on 
three factors in behaviour change, namely the person, the behaviour, and the 
environment.
52
 These factors dynamically interact with each other.
52
 Each theory 
however focuses on different aspects of the process. For instance, the self-efficacy/social-
cognitive theory focus on building efficacy beliefs.
52
 According to these theories, patients 
will achieve medication adherence if they believe that they have sufficient efficacy (e.g., 
skills and knowledge about treatment).
52
 Barclay and colleagues conducted a cross-
sectional study on the effect of self-efficacy to adherence behaviour among 185 human 
immunodeficiency virus infected (HIV-infected) patients. 
53
 Each unit increase of self-
efficacy score was associated with 30% increase of odds of good adherence measured by 
electronic pill bottle cap devices (OR=1.33, 95%CI 1.06-1.67).
53
  
Despite the numerous associations identified, behavioural theories and models 
have not necessarily translated into effective adherence interventions.
52
 Jones and 
colleagues reviewed 18 interventional studies based on HBM theories.
54
 Interventions of 
16 studies targeted beliefs on benefits of adherence, fifteen targeting beliefs about 
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susceptibility of disease, fourteen targeting perceived barriers of adherence, and eleven 
targeting perceived disease severity.
54
 The authors were not convinced that successful 
interventions on adherence were due to HBM elements in these studies.
54
 The authors 
also noted that measures of HBM elements were heterogeneous, making it difficult to 
compare results from different studies. 
54
 With respect to the models focusing on 
behavioural change and medication adherence interventions, evidence also tends to be 
weak.
52
 Although these models and theories help to understand potential factors required 
to improve medication adherence, further study is required to clarify the complexity of 
predicting or influencing medication taking behaviour.  
1.3 The influence of physicians on medication adherence 
Physicians may influence medication adherence in numerous ways. There are 
studies on choice of regimen complexity, professional training/specialty, 
cultural/language experience, and workload.
55, 56
 Frequent reminders from physicians 
have been associated with improved adherence to antihypertensives
57
 and patients 
recently started on statin medications were more likely to be adherent if the physician 
monitored their adherence status.
58
 Moreover, studies have shown that the number of 
visits to physicians is associated with higher medication adherence.
59, 60
  
The strongest evidence for the impact of physicians on medication adherence can 
be observed in studies asking patients about the interpersonal relationship with their 
physician.
61
 Many studies that use survey methods to collect information about 
relationships have found that trust levels are positively related to adherence.
62-67
 Similarly, 







 In theory, physicians possessing good communication skills (usually measured by 
patient satisfaction ratings) can forge trust with patients and strengthen the patient-
physician relationship.
72, 73
 Evidence for this association was supported by results of a 
meta-analysis that included studies examining physician communication as rated by a 
patient, health professional, or researcher. When communication was rated as poor, the 
risk of medication non-adherence increased by 19%.
73
 In addition, it was reported that 
training physicians in communication skills was linked to improved patient adherence 
(OR=1.62) comparing with physician receiving no training.
73
 One limitation is that most 
of these studies used self-report measures of adherence, which correlate poorly with 
objective measures such as refill records.
64, 74-78
 Perhaps there exists unidentified factors 
that are associated with stronger relationships and thus better adherence. Identification 
and analysis of such factors could help provider deeper understanding of the role of 
communication and trust. For example, physicians and patients of the same sex and/or 
age may relate more effectively but we do not know if this is associated with improved 
adherence.  
Evidence for the importance of the physician-patient relationship has also been 
suggested in other types of studies. An ongoing relationship between one family 
physician has been associated with improved satisfaction, trust, and effective 
communication in primary care.
79
 Also, having a single family physician can maximize 
the coordination of disease management and ensures the completeness of patient's health 
records.
80
 The ongoing relationship between physicians and patients is often measured by 
continuity of care (COC).
81
 Indeed, studies suggest that COC is associated with improved 
medication adherence, 
82-85
 and these observations align with the observed associations 
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between trust, communication, and medication adherence.
67, 69
 However, upon close 
examination, the measures used to support the relationship between COC and adherence 
in most population-based studies are based on methods that only identify the most 
commonly visited physician. Frequency of visits to a physician is undoubtedly part of the 
concept; however, COC also involves the delivery or coordination of multiple different 
services or dimensions of care for a given patient.
85
 Although various approaches to the 
measurement of COC have been examined,
82-85
 none have attempted to address the over-
reliance on physician visit claims to represent this complex concept. Another study in this 
PhD dissertation will examine a potential strategy to improve the validity of the 
traditional measure of COC and determine if a new approach can improve the 
performance of the measure.  
Despite the positive associations observed in multiple studies examining the 
importance of physician characteristics, skills, or their practice patterns, these studies 
often focused on a single factor, relied solely on self-reported adherence measures, or 
lacked adherence measurements of any kind. It is generally recognized that medication 
non-adherence is a multi-factorial problem that requires multi-faceted solutions.
30, 86
 As 
such, it would be contrary to conventional thinking to assume that activities delivered by 
a single physician would have an overwhelming effect on medication adherence.  
1.4 Review of study designs in adherence research 
Medication adherence has been studied with many different research designs. 
Basically, adherence studies have been conducted using two major approaches: 
Experimental or observational.  Experimental designs include randomized control trials 
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(RCT). Observational designs include cross-section studies, case-control studies, and 
cohort studies.  
RCTs are considered the gold standard design for clinical research studies.
87-90
 In 
a RCT design, study individuals are randomly assigned to the exposed and unexposed 
groups. The randomization process minimizes bias, and minimizes the impact of both 
measured and unmeasured confounding.
91, 92
 Among all designs, the RCT design offers 
the strongest inference of causality.
91, 92
 However, heterogeneity is common across 
published RCTs because of different populations, diseases, medications, interventions, 
and adherence outcomes.
30
 These differences make it virtually impossible to compare or 
pool results crossing disease areas and therapeutic classes, even within the same disease 
area.
30
 In addition, RCTs in adherence research have been often limited by small sample 
sizes and short follow-up periods.
25, 26, 93-95
 Also, an RCT design is difficult to implement 
if multiple factors are to be examined in the same study.  
Cross-sectional studies are commonly used in adherence research, in particular for 
developing hypotheses and assessing prevalence of non-adherence at a certain point in 
time. In a cross-sectional study, participants are analyzed at one particular time, i.e., both 
exposures and outcomes are measured at the same time.
87-89
 As such, it offers a “snap-
shot” of disease prevalence and coexisting factors, and thereby provides an economical 
way to explore the association between an outcome of interest and potential predictors.
87-
89
 However, the associations found in these studies cannot be interpreted as causal 
relationship due to limitations of the research design.
89
 In addition, selection bias, and 





In case-control studies, participants are initially grouped by outcome of interest.
87, 
89
 Participants who developed the outcome are assigned to the case group. Those who did 
not develop the outcome are assigned to the control group.
87, 89
 The case and control 
groups are then compared for the proportion of participants who were exposed to one or 
multiple interested explanatory factor(s).
87, 89
 To establish a temporal relationship, the 
exposure has to occur before the outcome. Controls are matched to cases on important 
variables such as date of entry, or length of follow-up, and thus are assigned the matching 
index date.
87, 89
 Case-control studies can be used to evaluate associations when other 
study designs are not feasible, or not ethical. In addition, these studies are often used 
when the outcome of interest is rare.
87-89
 The case-control study design offers efficiency 
in developing hypotheses and examining multiple predictors with small sample size.
89
 
However, its primary limitation with respect to medication adherence studies relates to 
the short time period (usually several months) used to assess exposure.
89
 Medication 
adherence is measured over an extended period of time, often one year, so the short 
exposure window in case-control studies limits opportunity for measurement.
89
 
Among observational study designs, cohort studies are commonly used in 
medication adherence research.
96, 97
 Cohort studies are similar to RCTs in that the study 
individuals are free of the outcome on entry, and comparator groups are stratified by 
exposure (i.e., exposed vs unexposed).
87, 89
 Cohort studies can be classified into 
prospective cohort studies, and retrospective cohort studies.
87-89
 A prospective cohort 
study begins when none of the participants have developed the outcome of interest. 
Prospective design guarantees the temporal relationship, collects pre-specified data (both 
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clinical and demographic), and strengthens the argument of causality. However, 
prospective studies are often plagued by high drop-out rates during follow-up.  
A retrospective cohort is performed after study outcomes have already occurred. 
Retrospective cohort studies are extremely popular designs in adherence research.
98
 Well-
designed retrospective cohort studies have advantages over prospective cohort studies in 
some situations, in particular when data is collected from administrative databases. First, 
data on medication dispensations is pre-collected so researchers do not have to wait for 
the duration of follow-up as in prospective studies. Second, retrospective studies 
frequently enable larger sample size. For example, in Czarny’s review the median size of 
the retrospective studies was 5,263 [216 to 9,256, interquartile range (IQR) =716], as 
opposed to the median size of 1,981 (12 to 15,157, IQR=6,418) among prospective 
studies.
98
 Third, retrospective studies are more flexible in extending the length of data 
collection as long as historical data is available. In Czarny’s review, the median length of 
data collection period was 1,187 days (821 to 2,253, IQR=838) among retrospective 
cohort studies, as opposed to the median length of 701 days (90 to 2284, IQR=548) 
among prospective studies.
98
 With the lengthier data collection, researchers can more 
easily conduct long-term evaluations of medication adherence and its impact on clinical 
outcomes.   
In cohort studies (and all other observational designs), study individuals are not 
randomly assigned to the exposure group or the control. As a result, most well-designed 
cohort studies attempt to adjust for multiple confounding factors. Regardless, selection of 
patients into the exposure group can be due to factors not observed by researchers. 
LaFleur and colleagues illustrated how unmeasured confounding likely caused an 
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overestimation of the benefit of medication adherence.
99
 For example, patients who 
exhibit high adherence to antihypertensive medications have lower risks for adverse 
outcomes (i.e., hospitalization, myocardial infarction, and mortality).
100
 However, this 
relationship is likely confounded by an unmeasured “healthy user” effect.
99
 Adherent 
patients likely adopted healthier behaviours such as exercise, diet, or quitting smoking). 
In this retrospective cohort study, the authors found that the association between optimal 
adherence and adverse outcomes did not change after controlling for blood pressure 
measures during follow-up.
99
 As such, the reduced risk to adverse outcomes may be 
largely due to an unmeasured “healthy user” effect rather than from reduced blood 
pressure due to regular use of medications.
99
  
Researchers have devised various methods to deal with the healthy user effect in 
adherence research. One strategy is to adjust unmeasured confounding by the 
instrumental variable method.
92, 101
 An instrumental variable is a factor related to 
exposure but not outcome.
92, 101, 102
 Potential instrumental variables can be calendar time, 
physician preference, geographic distance, or insurance plan.
103
 
1.5 Aims and objectives  
The aim of this PhD program was to evaluate physician influence on medication 
adherence and determine if their influence addresses the substantial gap in performance 
of population-based prediction models.   
Research objectives 
1) To investigate a practice related factor, continuity of care. 
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 1a) to determine if high Usual Provider Continuity Index (UPCI) values predict 
physicians who deliver different clinical services;  
1b) to compare UPCI with an integrated COC measure in a multivariable model of 
patients receiving statin medications. 
2) To examine demographic factors with the focus on age and/or sex concordance (same 
age range and/or same sex) between physicians and patients. 
3) To explore the extent to which ‘physician effects’ may help explain variance in patient 
adherence to statin medications. 
3a) to examine physician effect unexplained by patient and physician characteristics; 




Three studies were conducted from different perspectives in this PhD dissertation. 
The first (Chapter Two) investigated a practice related factor, continuity of care. The 
second (Chapter Three) examined demographic factors with the focus on age and sex 
concordance between physicians and patients. The third (Chapter Four) examined overall 
physician influence adjusted by physician characteristics. 
Publications 
Chapter Two and Three are two manuscripts that have been submitted to journals, 
and are currently under review. Chapter Four contains research from which multiple 
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manuscripts are under development. These chapters are corresponding to the research 
objectives of my PhD research projects. Contribution in detail (of Shenzhen Yao and the 
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Continuity of care (COC) is considered an important determinant of medication 
adherence based on measures such as the usual provider continuity index (UPCI) that are 
derived exclusively from physician visit claims. This study aimed to: a) determine if high 
UPCI values predict physicians who deliver different clinical services; and b) compare 
UPCI with an integrated COC measure in a multivariable model of patients receiving 
statin medications. 
Methods:  
This was a retrospective cohort study of new statin users between 2012 and 2017 
in Saskatchewan, Canada. We calculated sensitivity/specificity of a high UPCI value for 
predicting physicians who were prescribers of statins and/or providers of complete 
medical examinations.  Next, we used logistic regression models to test two measures of 
COC (high UPCI value or an integrated COC measure) on the outcome of optimal statin 
adherence (proportion of days covered ≥80%). The DeLong test was used to compare 
predictive performance of the two models.   
Results:  
Among 55,144 new statin users, a high UPCI was neither a sensitive or specific 
marker of physicians who prescribed statins or performed a complete medical 
examination. The integrated COC measure had a stronger association with optimal 
adherence [adjusted odds ratio (OR) =1.56, 95% confidence interval (CI) 1.50 to 1.63] 
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than UPCI (adjusted OR = 1.23, 95% CI 1.19 to 1.28), and improved predictive 
performance of the adherence model.    
Conclusion:  
The number of physician visits alone appears to be insufficient to represent COC. 
An integrated measure improves predictive performance for optimal medication 




Studies suggest that individual physicians can improve medication adherence by 
establishing continuity of care (COC) for their patients.
1-4
 The precise nature of this 
association is unknown but is likely mediated by factors promoting a strong relationship 
between patients and physicians.
5, 6
 Indeed, an ongoing relationship between a physician 
and a patient is associated with higher satisfaction, improved trust, and more effective 
communication.
7
 Having a single physician also helps ensure the completeness of a 




COC is a complex concept.
9
 Although previous studies have demonstrated a 
positive correlation with medication adherence, conventional measures of COC have 
limitations that may be improved upon using a more comprehensive definition that is 
specific for medication adherence.
1-4
 COC is commonly measured by the usual provider 
continuity index (UPCI) .
9, 10
 UPCI is determined by a simple calculation of the 
percentage of visits to a specific physician relative to all other physician visits in a given 
time period.
9, 10
 As a result, it is highly influenced by total number of visits, and total 
number of different physicians.
10
 For example, a patient with multiple chronic conditions 
may visit many different physicians in a given year. In this situation, the UPCI for that 
patient’s regular physician may be low because the denominator (i.e., total number of 
visits with all physicians) is increased compared to a different patient who visits a single 
physician exclusively. Moreover, since the UPCI is based solely on visit occurrences, the 
nature of the visits is not accounted for. The UPCI approach does not consider 
prescribing activities despite evidence suggesting that individuals are more likely to be 
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adherent if their regular physician is the prescriber of their treatment regimes.
11
 Certainly, 
it seems logical that a continuity of care measure applied to a cohort of medication users 
should consider the physician’s prescribing activities relating to the drug(s) of interest.  
Further, the UPCI does not represent clinical services such as complete medical 
examinations (CME), which would be expected from a patient’s regular physician. 
Although this activity has been identified as a measure of COC, few studies have 
examined the impact of CME providers on medication adherence.
12, 13
 Although previous 
studies have attempted to improve on measures of COC with minimal success, the 
updated definitions have continued to focus on visit frequency only.
1, 4
 
We hypothesized that 1) a high UPCI value will perform poorly in predicting 
physicians who provide other clinical activities to specific patients (i.e., prescribing, and 
complete medical examinations); and 2) an integrated COC measure consisting of 
physician visits, prescribing, and claims for a complete medical examination would result 
in a stronger association with medication adherence, and improve the predictive ability of 
medication adherence models. The objectives of this study were: 1) to examine the 
accuracy of UPCI for predicting other COC-related clinical activities, including 
prescribing statin medications, and/or performing complete medical examinations; and, 2) 
to determine if an integrated measure of COC is superior to UPCI in discriminating 
adherent statin users, and therefore improving the predictive performance of a covariate-





Study data were extracted from administrative databases for the province of 
Saskatchewan, Canada. These databases include the person registration file, the physician 
service claims file, the hospital discharge abstract database, the emergency service file 
and the prescription drug claims files.
14
 The person registration file captures birth, sex, 
rural/urban residence, health insurance coverage start/end dates, and median household 
income quintiles estimated by linking the first three digits of postal code to Statistics 
Canada Census data. The physician service claims file captures the date of the service, 
the type of the service (in-hospital or out-patient), the diagnosis of the service using 
three-digit International Statistical Classification of Diseases and Related Health 
Problems, 9th Revision codes (ICD-9),
15
 the encrypted identification code of the service 
provider, the specialty of the service provider, the fee code for billing, and the type of 
payment to the provider. The hospital discharge abstract database captures admission and 
discharge date, up to 25 diagnoses by ICD-9 or International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision, Canada (ICD-10-CA) codes,
15, 16
 
and an indicator on whether the recorded event was for acute care or alternative care (i.e., 
a patient was occupying a bed in a hospital and did not require the intensity of services as 
for acute care).
17
 The emergency service file captures admission and discharge date of 
visits to emergency departments. The prescription drug claims files capture dispensations 
of prescription medications in out-patient settings. Each claim includes a Health Canada 
drug identification number (DIN), a dispensation date, the quantity dispensed, total cost 
38 
 
(including medication acquisition cost and markup/dispensing fee), and the proportion 
covered by government insurance. 
Study design and population 
A retrospective cohort was conducted consisting of individuals who initiated a 
new 3-hydroxy-3-methylglutaryl-coenzyme (HMG CoA) reductase inhibitor medication 
(i.e., statin) between January 1, 2012, and December 31, 2017. The new initiation was 
defined as receiving no dispensations for a statin medication in the five years prior. We 
chose to study statin medications because they are prescribed for chronic treatment only, 
they had no therapeutic equivalent during the period of study, they are prescribed to a 
large percentage of the population, and they are associated with reduced morbidity and 
mortality from atherosclerotic cardiovascular disease.
18
 
The date of the earliest dispensation of a statin medication was the index date, and 
patients were followed for 365 days. The cohort exclusion criteria were: 1) missing age 
or sex information in the person registration file; 2) age on the index date less than 18 
years; 3) not continuously registered in the provincial health plan during five years prior 
to the index date, or the one-year follow-up period; 4) admitted to a long term care 
facility within five years prior to the index date, or 365 day follow-up period; 5) admitted 
to an out-province hospital during the 365 day follow-up; 6) a claim for pregnancy (ICD-
9: 641-676, V27; ICD-10 and ICD-10-CA: O1, O21-95, O98, O99, Z37) in the 365 days 
prior to the index date or in the 365 days after the index date;
19
 or 7) no visits to a general 
practitioner (GP)  during the 365 day follow-up period. 
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COC measures and physician classifications 
For each patient, we defined the following COC measures: a) usual care provider 
and the UPCI;
9, 10
 b) usual statin prescriber (USP); c) complete medical examination 
provider (CMEP);
12
 and d) an integrated COC measure that combined all three measures 
(i.e., a single GP identified as the usual care provider, USP, and CMEP).  
For determination of the usual care provider, we first identified all distinct service 
claims provided by GP physicians during each patient’s follow-up period. Multiple 
claims by the same GP for the same patient on the same date were treated as one visit.
10
 
Service claims were not included if: 1) the claim was marked as invalid in the database; 2) 
if the service was provided to a hospitalized patient; or 3) if the claim originated from an 
out-of-province provider. For each patient, a usual care provider was identified as the GP 
with the most frequent visits during the follow-up period. In the case of a tie, multiple 
GPs could be assigned as usual care providers for a given patient.  






 where nmax was the number of visits between the patient and the most 
frequently visited GP (i.e., the usual care provider) within the follow-up period and N 
was the total number of visits between the patient and all GP physicians visited within the 
same period. Based on the calculated UPCI value, each patient was assigned into a high 
or low UPCI category using the median UPCI value of the study cohort as the cut off. 
This process has been used previously to measure COC.
10
  
The usual statin prescriber (USP) was any type of physician (i.e., not necessarily a 
GP) of a patient listed on the highest number of statin dispensation claims during the 
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follow-up period. In cases where a tie was observed, more than one physician was 
identified as USPs. Complete medical examination providers (CMEP) were identified on 
at least one claim for a complete medical examination during the follow-up period (i.e., a 
fee code billed for complete assessment, or chronic disease management).
20
 A patient 
could have multiple CMEPs within the study period,
12
 and any type of physician listed in 
the physician service claims was considered (i.e., not necessarily a GP). Finally, we 
combined these definitions into an integrated COC measure (yes/no) depending on 





The study outcome was optimal adherence to statin medications defined as 
proportion of days covered (PDC) >=80%.
21, 22
 PDC was calculated for the 365-day 
period from the index date for each patient. As these drugs are typically prescribed once 
daily, the number of days supplied during this time was estimated from the total quantity 
of tablets dispensed.
23
 Quantities dispensed near the end of the follow-up period were 
truncated based on the number of days remaining in the follow-up period. Switching 
between statin medications was allowed. The total number of statin tablets dispensed was 
divided by 365 days (minus days spent in hospital) to obtain the adherence percentage. 




We built a multivariable model with covariates previously used to predict 
medication adherence from administrative databases.
24
 These covariates were organized 
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under a framework with five categories: patient, socioeconomic status, treatment, health 
care system, and condition factors.
24
 The covariates were measured in the period up to 
365 days prior to the index date if not otherwise specified. The patient covariates 
included age, sex, and residence (rural/urban) on the index date. The socioeconomic 
status covariates included income level, which was based on neighborhood median 
household income quintiles (lowest=1, highest=5) on the index date.
25, 26
 The treatment 
covariates included number of distinct prescription medications, which were determined 
from unique drug identification numbers. The health care system covariates included 
number of out-patient visits (to GPs and to specialists, respectively), and percentage of 
prescription medication cost paid by government health insurance. The condition 
covariates included number of hospitalizations for acute care, number of emergency 
department visits, Charlson comorbidity score, and clinical conditions (yes/no) identified 
from published models of medication adherence.
27
 These clinical conditions included 
osteoporosis, rheumatoid arthritis, hypertension, stroke, ischemic heart disease, acute 
myocardial infarction, heart failure, multiple sclerosis, Parkinson’s disease, Alzheimer’s 
disease and dementia, epilepsy, asthma, chronic obstructive pulmonary disease, diabetes, 
mood and anxiety diseases, schizophrenia, and cancer.
19
  These clinical conditions were 
identified using validated case definitions provided by the Canadian Chronic Disease 
Surveillance System and were based on diagnoses recorded in the service claims file and 
hospital discharge abstract database, and medications in the prescription drug claims 








We described the baseline characteristics of the study cohort using descriptive 
statistics for all patients as well as subgroups based on COC measured by UPCI and the 
integrated COC measure. These characteristics included median age, percentages by sex 
(female/male), residence (rural/urban), and median income quintile (1= lowest, 
5=highest). We also described the use of health services, including the percentage of 
patients with one or more hospitalizations for acute care (0, or >=1), the percentage with 
one or more visits to emergency department, the median number of visits to GPs, and the 
median number of visits to specialists. 
To determine if a high UPCI value was predictive of patients receiving various 
clinical activities from a given physician, we calculated its sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), and the Kappa statistic 
28
 for predicting the usual statin prescriber (USP), the CMEP, and the integrated COC 
measure as the reference standards. 
Next, we built logistic regression models to test the effect by two measures of 
COC on optimal adherence to statins: a high UPCI value (representing traditional 
measures of COC) versus presence of the integrated COC measure. Both unadjusted and 
adjusted models were tested separately for each COC measure as the independent 
variable. The unadjusted models had a single COC measure as the explanatory variable. 
The adjusted model had the COC measure plus all covariates described above. To 
maximize the control for confounding, all covariates were included regardless of 
statistical significance in each of the two adjusted models, except for those exhibiting 
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collinearity with the independent variable. Multicollinearity between COC and the 
adherence covariates were examined by the variance inflation factor (VIF) obtained from 
a regression model. If the VIF value was greater than 2.5, the covariate was removed.
29
 
Odds ratios (ORs) and 95% confidence intervals (95% CIs) are reported. 
We performed the DeLong test to compare predictive performance of the two 
adjusted models that each contained a COC measure.
30
 The model that produced a larger 
estimate of the area under the receiver operating characteristic curve (AUROC) was 
considered to have better predictive performance if the difference in the AUROC 
estimates was statistically significant (p<0.05).
30
  
To test the consistency of our results, several subgroup and sensitivity analyses 
were conducted. In subgroup analyses, we assessed the impact of an integrated COC 
measure (yes/no) among patients with a high UPCI and with a low UPCI separately. We 
also assessed the impact of UPCI (high/low) among patients with and without integrated 
COC. We conducted sensitivity analyses for a modified adherence measure, which was 
recalculated without allowing accumulated supplies between refills, and changed the 




 percentile rather than the median. SAS 





Ethics approval was granted by the University of Saskatchewan Biomedical 
Research Ethics Board (certificate number: 14-143). Data was accessed at the 
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Saskatchewan Health Quality Council under data sharing agreements with the 
Saskatchewan Ministry of Health and eHealth Saskatchewan. 
2.4 Results 
Overall 180,010 patients received statin medications between January 1, 2012, 
and December 31, 2017. Among them, 21,149 (11.8%) were excluded due to missing 
demographic information, death during the study period, or a lack of continuous 
beneficiary status (Figure 2.1). The final cohort was comprised of 55,144 (30.6% of 
180,010) new users of statin medications. The median age of the final cohort at the index 
date was 59.0 years [interquartile range (IQR) 51.0 to 67.0], 44.2% (24,385/55,144) were 
females and 32.3% (17,811/55,144) lived in a rural setting. The median number of GP 





Figure 2.1: Study flow chart. 
 
a
Index date = the earliest date receiving a statin medication between January 1st, 2012 and December 31st, 
2017; 
b




Table 2.1: Baseline characteristics of the final cohort. 
Baseline characteristicsa All Patients grouped by UPCIb Patients grouped by integrated 
COCc  
  High(>=0.82) Low(<0.82) Yes No 
 n=55,144 n=27,859 n=27,285 n=15,579 n=39,565 
      












      
Females (n, %) 24,385 (44.2) 11,635 (41.8) 12,750 (46.7) 6,840 (43.9) 17,545 (44.3) 
      
Patients with one or 
more hospitalizations 
for acute care (n, %)  
 
12,528 (22.7) 6,203 (22.3) 6,325 (23.2) 2,626 (16.9) 9,902 (25.0) 
      
Visits to GPse,  
median (IQR) 
6.0 (3.0, 9.0) 5.0 (3.0, 9.0) 6.0 (3.0, 10.0) 6.0 (3.0, 9.0) 5.0 (3.0, 9.0) 
      
Visits to specialists,  
Median (IQR) 
2.0 (0.0, 6.0) 2.0 (0.0, 6.0) 2.0 (0.0, 6.0) 2.0 (0.0, 5.0) 2.0 (0.0, 7.0) 
      
Patients with one or 
more visits to 
emergency department 
(n, %) 
11,450 (20.8) 5,519 (19.8) 5,931 (21.7) 2,739 (17.6) 8,711 (22.0) 
      
Patients by income level 
(n, %) 
     
1 (lowest) 10,339 (18.7) 4,787 (17.2) 5,552 (20.3) 2,675 (17.2) 7,664 (19.4) 
2 10,207 (18.5) 5,058 (18.2) 5,149 (18.9) 2,761 (17.7) 7,446 (18.8) 
3 10,093 (18.3) 5,182 (18.6) 4,911 (18.0) 2,942 (18.9) 7,151 (18.1) 
4 11,289 (20.5) 5,897 (21.2) 5,392 (19.8) 3,251 (20.9) 8,038 (20.3) 
5 (highest) 10,268 (18.6) 5,456 (19.6) 4,812 (17.6) 3,052 (19.6) 7,216 (18.2) 
missing 2,948 (5.3) 1,479 (5.3) 1,469 (5.4) 898 (5.8) 2,050 (5.2) 
      
Patients by residence 
location (n, %) 
     
Rural 17,811 (32.3) 8,666 (31.1) 9,145 (33.5) 4,364 (28.0) 13,447 (34.0) 
Urban 37,333 (67.7) 19,193 (68.9) 18,140 (66.5) 11,215 (72.0) 26,118 (66.0) 
a Median age, number of females, residence (rural/urban), and patient income level were measured on the index date; Number of 
patients with one or more hospitalizations, median visits to GPs/specialists, patients with one or more visits to emergency departments 
were measured within one year prior to the index date; bUPCI = usual provider continuity index; cCOC = continuity of care;  




A single usual care provider (i.e., the GP with the highest number of visits) was 
identified for 92.6% (n=51,071) of the cohort, whereas 7.4% (n=4,073) of patients had 
two or more GPs tied for the highest number of visits. The median UPCI among the 
cohort was 0.82 (IQR 0.62 to 1.00), meaning half of all patients visited the same 
physician for 82% to 100% of their total GP visits during the one-year follow-up period.  
Similarly, a single usual statin prescriber (USP) could be identified for the vast majority 
of patients (n=52,693, 95.6%). In contrast, only 22,017 (39.9%) of the patients received 
complete medical examinations from a GP physician. The rest 33,127 (60.1%) of the 
patients either had no complete medical examinations during the follow-up period or 
received the examinations from a specialist. Finally, 15,579 (28.3%) of the patients were 
classified as receiving integrated COC, defined as having a single GP for their usual care 
provider, USP, and CMEP. 
A high UPCI (i.e., above the median value) was neither a sensitive or specific 
marker to identify a physician who was also the USP or CMEP [Table 2.2]. The 
sensitivity ranged from 0.55 (95% CI 0.55 to 0.56, using UPCI to predict usual statin 
provider) to 0.58 (95% CI 0.58 to 0.59, using UPCI to predict integrated COC). The 
specificity ranged from 0.52 (95% CI 0.51 to 0.52, using UPCI to predict CMEP) to 0.61 
































 (0.60, 0.62) 
0.78 
 (0.77, 0.78) 
0.35 
 (0.35, 0.36) 
0.13 
 (0.13, 0.14) 







 (0.51, 0.52) 
0.39 
 (0.39, 0.40) 
0.67 
 (0.66, 0.68) 
0.06 
 (0.05, 0.07) 







 (0.52, 0.53) 
0.33 
 (0.32, 0.33) 
0.76 
 (0.76, 0.77) 
0.09 
 (0.08, 0.09) 
a
UPCI = usual provider continuity index; 
b
USP=usual statin prescriber; 
c
CMEP = complete 
medical examination provider; 
d
COC = continuity of care; 
e
CI = confidence interval; 
f
PPV=positive predictive value; 
g
NPV=negative predictive value. 
 
Both high UPCI and the integrated COC measure showed statistically significant 
associations with optimal adherence to statin medications. Optimal adherence was 
observed in 56.0% (15,606/27,859) of patients with a high UPCI versus 49.9% 
(13,604/27,285) of those with low UPCI (unadjusted OR = 1.28, 95% CI 1.24 to 1.32, 
adjusted OR =1.23, 95% CI 1.19 to 1.28). In comparison, a stronger association with 
optimal adherence was observed when UPCI was included in the integrated COC 
measure (unadjusted OR = 1.45, 95% CI 1.40 to 1.51, adjusted OR=1.56, 95% CI 1.50 to 
1.63).  Optimal adherence was observed in 59.5% (9,277/15,579) of patients meeting the 
integrated COC criteria versus (versus 50.4%, 19,933/39,565) of those who did not. 
The significant association between the integrated measure of COC and optimal 
adherence was consistently observed among subgroups with either a high UPCI value 
(adjusted OR=1.48, 95% CI 1.40 to 1.56) as well as those with a low UPCI value 
(adjusted OR=1.60, 95% CI 1.51 to 1.70). In contrast, the impact of a high UPCI 
appeared to have a weaker impact when tested in subgroups based on the presence or 
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absence of integrated COC (OR= 1.13, 95% CI 1.06 to 1.21; and OR= 1.22, 95% CI 1.17 
to 1.27; respectively) [Table 2.3]. Finally, patients receiving integrated COC with a low 
UPCI score had 31% higher odds of achieving optimal adherence versus those without 
integrated COC but a high UPCI value (OR = 1.31, 95%CI 1.24 to 1.39). In the Delong 
test, the adjusted model using the integrated COC term significantly improved the 
AUROC (+0.006, χ2 statistic = 38.8, p < 0.0001) compared to the model using the UPCI 
measure of COC.  
Table 2.3: Odds ratios (OR) and 95% confidence intervals (95% CI) for the 
association of measures of COC with optimal adherence (Proportion of days 














 1.45 (1.40, 1.51) 1.56 (1.50, 1.63) 




1.48 (1.40, 1.56) 
Among patients with low UPCI 
 
1.60 (1.51, 1.70) 
UPCI 1.28 (1.24, 1.32) 1.23 (1.19, 1.28) 
Patients presenting integrated COC 
 
1.13 (1.06, 1.21) 
Patients not presenting integrated COC 
 
1.22 (1.17, 1.27) 
aOR = odds ratio; bCI = confidence interval; cCOC = continuity of care; dIntegrated COC = having a single physician identified as the 
usual care provider, the usual statin prescriber, and the complete medical examination provider; eUPCI = usual provider continuity 
index; fCovariates in the adjusted model included 1) age, sex, residence (rural/urban), and  income level (i.e., the neighborhood 
median household income quintile, lowest=1, highest=5) on the index date; 2) the following were measured within 365 days prior to 
the index date: number of hospitalizations, number of out-patient visits (to GPs and to specialists, respectively), number of emergency 
department visits, Charlson comorbidity score, number of distinct prescription medications (by drug identification numbers), and 
percentage of prescription medication cost paid by government health insurance; and 3) a list of chronic conditions identified between 
January 1st, 1996, and the index date, including osteoporosis, rheumatoid arthritis, hypertension, stroke, ischemic heart disease, acute 
myocardial infarction, heart failure, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and dementia, epilepsy, asthma, 




In sensitivity analyses, the effect of UPCI and integrated COC were similar to the 
primary analysis when the days supply of statin medications were not allowed to be 
accumulated between refills. Also, we changed the threshold to define “high UPCI” from 
the median value to the 25
th
 percentile. In this case the association of the UPCI measure 
on optimal adherence was stronger (adjusted OR = 1.39, 95% CI 1.34 to 1.45) but weaker 
when the threshold was changed to the 75
th
 percentile (adjusted OR = 1.09, 95% CI 1.05 
to 1.13). Regardless of the threshold changes, the impact of the UPCI alone was still 
weaker than the effect by the integrated COC measure.  
2.5 Discussion  
COC is considered to be an important determinant of medication adherence. It 
aligns with the paradigm of patient-centred care through coordination of services, 
especially when multiple providers are involved.
10
 Quantitative studies appear to have 
confirmed this association with adherence; however, the most commonly used measure, 
the UPCI, is derived exclusively from the number of physician visits and fails to account 
for the coordination of care that is fundamental to the spirit of COC.
1-4
 Our results 
indicate that a high UPCI value did not identify physicians who were providing core 
services (for example, prescribing statins to a cohort of new statin users or providing 
complete medical examinations). However, adding these clinical activities to the UPCI 
definition of COC resulted in a stronger association with medication adherence and 
significantly improved the predictive power of a medication adherence model.  Further, 
the integrated COC measure added significant discrimination even when patients were 
stratified by high or low UPCI values. Our findings align with studies of patient-centered 
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medical homes (PCMH) in which medication adherence appeared to be improved by care 
coordination.
27, 32
   
Despite the vast number of variables linked to medication adherence from 
published studies, almost all confer weak predictability in multivariable models.
33-35
 
Wong and colleagues conducted a population-based study with many patient-level factors 
including demographic characteristics (e.g., age, sex, and marital status), comorbidities 
(e.g., vascular disease, mental illness, and chronic lung or renal disorders), and regimen 
complexity.
34
 The study also included clinical factors such as disease severity, and 
laboratory test results. Yet the authors found that all these variables only explained 2.9% 
of the adherence variation between patients.
34
 Indeed, one of the major gaps in 
medication adherence research is the inability to explain more than a fraction of the 
variance observed with respect to adherence outcomes.  We believe that adherence 
research needs to improve on the poor predictive ability of population-based models, 
which will require the identification of new variables as well as improving upon 
traditional measures such as COC.  
 Our study was not without limitations. First, the effect of COC on adherence was 
not adjusted by GP-related characteristics (e.g. age, sex, medical training background, 
workload, and prescribing habits), although the literature suggests that these 
characteristics may affect medication adherence.
11-13, 36
 Second, GP physicians paid on 
salary (rather than fee-for service) are not required to submit service claims. As a result, 
the number of visits may have been underestimated. Alternatively, GPs paid by a fixed 
salary may perform differently than GPs paid by fee-for-service but that factor could not 
be assessed.
37
 Third, the association between the integrated COC measures and adherence 
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may not be causal. Having all services from the same GP could be a sign of a successful 
relationship rather than its cause. Nonetheless, COC measures have been used in many 
studies on medication adherence with positive findings and have a strong theoretical link 
to the origins of the problem.
1-4
 Finally, including complete medical examination (CME) 
in the integrated COC measure may have limitations. One potential issue is that CME 
may confound the adherence outcome. It is possible that sicker patients were more likely 
to have a complete medical examination, and the literature suggests that sicker patients 
were more likely to be adherent than healthier patient.
24
  Another limitation is the 
generalizability of applying the integrated COC measure to other Canadian provincial 
settings. In some jurisdictions, CME is not included as a benefit of health insurance plans, 
or is included with restrictions on who should receive it.  Under these circumstances, it is 
certainly possible that CME may not be the ideal component of an integrated COC 
measure despite the positive results from this study.  On the other hand, the improvement 
associated with the CME may not have been due to this specific service per se, rather it 
may have indicated evidence for patient-physician relationships that include a diverse 
variety of services (i.e., from prescribing statins to other types of examinations).           
Despite these limitations, we improved upon an existing measure of COC that not 
only produced a robust odds ratio, but also improved the predictive success of an 
adherence model containing a large number of established covariates. Our findings do not 
merely identify a new variable for models of medication adherence but they contribute to 
an important and elusive goal of explaining the phenomenon within a framework that 




The most common approach for measuring COC in adherence models fails to 
account for a key principle of service coordination. An updated measure that integrates 
other clinical services with physician visits is more consistent with the concept of COC 
and the value of patient-centred care. In addition, the use of an integrated measure of 
COC provided better discrimination of adherent patients and improved predictive 
performance of a covariate-adjusted adherence model.  An integrated measure should be 
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Objective: To determine the impact of age and sex concordance on optimal adherence to 
statin medications. 
Design: A retrospective cohort study. 
Setting: Population-based health administrative data from Saskatchewan, Canada. 
Participants: Patients newly initiated on statin medications between January 1, 2012 and 
December 31, 2017.  
Explanatory variables: Sex concordance (i.e., same sex) and age concordance (i.e., age 
within five years) between patients and prescribers. 
Main Outcome Measure(s): Optimal adherence (i.e., proportion of days covered ≥ 
80%) measured at one year after the first statin claim. 
Statistical analysis: Multivariable logistic regression models using generalized 
estimating equations. 
Results: Among 51,874 new statin users, 20.6% (n=10,710) were age concordant with 
prescriber. The vast majority of age concordance occurred in patients younger than 66 
years (88.6%, 9,486/10,710). Sex concordance was observed in 62.8% (n=32,551) of 
patients and age-sex combined concordance in 13.2% (n =6,856). Among patients 
younger than 66 years (n= 36,641), age concordance did not have a significant impact on 
optimal adherence [adjusted OR (aOR) = 1.02, 95%CI 0.97 to 1.07]. The association of 
sex concordance (aOR=1.05, 95%CI 1.00 to 1.11), and age-sex combined concordance 
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(aOR = 1.05, 95%CI 0.99 to 1.12) within adherence were stronger than age concordance 
but failed to reach statistical significance by a very small margin. 
Conclusions: Age and sex concordance were not statistically significant predictors of 
optimal statin adherence. However, a weak signal was detected for sex concordance. 






Over decades of research on medication adherence, the impact of age and sex has 
been evaluated countless times without a clear and consistent signal.
1
 Mathes and 
colleagues concluded that the effects of patient age on medication adherence were 
heterogeneous after reviewing 22 systematic reviews published between January 1990 
and June 2018.
2, 3




Although age and sex of patients appear to have weak influences on medication 
adherence, few studies have evaluated the extent to which they may influence medication 
adherence through interactions with other factors. The existence of interactions between 
demographic characteristics may be important for medication adherence. For example, 
Schoenthaler and colleagues found that African-American patients under care of white 
physicians (i.e., discordance on ethnicity) had lower medication adherence compared to 
white patients under care of white physicians.
4
 Presumably, this ‘concordance’ of race 
may have facilitated a more effective or trustful relationship between physicians and 
patients, improving medication adherence.
4, 5
 Indeed, a strong physician-patient 
relationship has clearly been associated with high medication adherence as multiple 
studies have identified trust and communication between patients and physicians as 
important factors.
1, 6-11
 Thornton and colleagues’ found that patient-physician 
concordance on age and sex has positive effect on communication and satisfaction of 
care.
12
 However, despite the strong connection between communication and medication 
adherence, the impact of age and/or sex concordance on medication adherence to 
prescribed medications has not been examined.  
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Based on these findings, we hypothesized that age and/or sex concordance may 
also be associated with medication adherence through the presumed mechanism of 
facilitating a more effective patient-physician relationship. The aims of this study were: 1) 
To describe the prevalence of age and/or sex concordance between prescribers and 
patients initiating statin medications; 2) To determine if age concordance, sex 
concordance, or age-sex combined concordance is associated with the occurrence of 
optimal adherence within the first year since initiating statin therapy. 
3.3 Methods  
Data sources 
The study was conducted using administrative databases for Saskatchewan, 
Canada. These databases, linked by a common encrypted identification number for each 
patient, include the provincial health insurance registry file, the physician service claims 
file, the physician registry file, the hospital discharge abstract database, the emergency 
services file, and the prescription drug claims files.
13
 The provincial health insurance 
registry file contains birth month/year, sex, rural/urban residence, provincial health 
insurance coverage start and end dates, and dissemination area (smallest standard 
geographic area for census data defined by Statistics Canada)
14
 code of residence. The 
latter is used to assign area-level median household income based on 2006 census data.
15
 
The physician service claims file contains the date of the service, setting (in-hospital or 
out-patient), diagnosis (using three-digit International Classification of Diseases (ICD-9) 
codes),
16
 physician identification number (encrypted), physician specialty, the billing 
code pertaining to the service provided, and the remuneration type of the provider [fee-
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for-service (FFS) /non-fee-for-service type (NFFS)]. Although non-fee-for-service 
physicians are encouraged to submit “shadow claims”, compliance is not enforced, and 
not all claims are captured. However, the percentage of missing shadow claims is not 
likely to be large, given previous Canadian research.
17
 The physician registration file 
contains physicians’ birth year, sex, and an indicator to distinguish general physicians 
(GPs) from other specialty physicians. It also provides information on country of medical 
training of physicians in Saskatchewan. The hospital discharge abstract database contains 
admission and discharge dates, up to 25 diagnostic codes (ICD-9 (2001 and before) or 
ICD-10-CA (after 2001),
16, 18
 and an indicator about the event type (i.e., whether it was 
for acute or alternative care, of which a patient occupied a bed but did not require the 
intensity of services as for acute care).
19
 The emergency service file provides admission 
and discharge date of visits to emergency departments. The prescription drug claims files 
capture dispensation claims of prescription medications, each containing a Health Canada 
drug identification number (DIN), a dispensation date, the quantity dispensed, total cost 
(including medication acquisition cost and markup/dispensing fee), and the proportion 
covered by government insurance. The drug files only contain claims in outpatient 
settings. 
Study design and population 
We conducted a retrospective cohort study of new statin users at least 18 years of 
age who received their first statin medication between January 1, 2012 and December 31, 
2017. New users were defined as receiving no dispensations for a statin medication in the 
previous five years. The date of the first dispensation of a statin medication was the index 
date, and the patients were followed for 365 days. For each patient, a single statin 
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prescriber was identified using the following criteria: a) the physician with a GP specialty, 
and b) the GP identified on the highest number of statin dispensation claims for a specific 
patient (compared to all other GPs) during the 365 day follow-up period. In 
Saskatchewan, GPs provide primary care to the majority of patients with chronic 
conditions.  
Exclusion criteria included: missing age or sex of patients or statin prescribers; 
unable to determine the remuneration type of statin prescribers; inability to follow 
patients between 1,825 days before and 365 days after the first statin claim due to loss of 
beneficiary status (including death), or admission to a long term care facility; patients 
admitted to an out-of-province hospital in the year after initiating the statin; a diagnosis 
of pregnancy (ICD-9: 641-676, V27; ICD-10 and ICD-10-CA: O1, O21-95, O98, O99, 
Z37) within one year before or after the index date; or if none of their statin prescribers 
was a GP physician. 
Patient and public involvement 
Patients and/or the public were not involved in the design or conduct of this study. 
Outcome measures 
The primary outcome was optimal adherence to statin medications defined by the 
proportion of days covered (PDC) of at least 80%.
20, 21
 PDC was measured over the 365 
days following the index date using the sum of the number of pills dispensed divided by 
365 (assuming once-daily satin dosing), deducting the number of days spent in a hospital 
for acute care if applicable.
22
 Pills dispensed during overlapping/early refills were 
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counted in the numerator for the primary analysis and removed in sensitivity analyses. 
Switching between different statin medications was allowed.  
Age/sex concordance between patients and their statin prescriber 
Age of each patient and their corresponding statin prescriber was determined on 
each patient’s index date. Patients were categorized as age-concordant if their age was 
within five years above or below the prescriber’s age; sex-concordance was assigned if 
the patient and the prescriber were of the same sex. Age-sex combined concordance was 
determined if both age and sex concordance were satisfied.  
Covariates 
Numerous patient and provider-related covariates were identified to minimize 
confounding based on previous studies.
1
 Covariates were measured during the 365 days 
prior to the index date if not otherwise specified. Patient-related covariates included 
patient characteristics [age, sex, and residence (rural/urban) on the index date]; 
socioeconomic status [income level based on census area-level median household income 
quintiles (lowest=1, highest=5) on the index date];
23, 24
 treatment factors [number of 
distinct prescription medications (by the Anatomical Therapeutic Chemical Classification 
System)
25
]; health care system factors [percentage of prescription medication cost paid by 
government health insurance], and patient health/health care utilization factors [number 
of out-patient visits (to GPs and to specialists, respectively), number of hospitalizations 
for acute care, number of emergency department visits, Charlson comorbidity score,
26
 
and presence of patient clinical conditions (yes/no) used in published models of 
medication adherence].
27
 The clinical conditions included osteoporosis, rheumatoid 
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arthritis, hypertension, stroke, ischemic heart disease, acute myocardial infarction, heart 
failure, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and dementia, 
epilepsy, asthma, chronic obstructive pulmonary disease, diabetes, mood and anxiety 
diseases, schizophrenia, and cancer.
27
 Conditions were identified using validated case 
definitions developed by the Canadian Chronic Disease Surveillance System and were 
based on diagnoses recorded in the service claims file, hospital discharge abstract 






Prescriber-related covariates included the statin prescribers’ age and sex on the 
index date, country of medical graduation, as well as a categorical variable of 
remuneration type [fee-for-service (FFS) or non-fee-for-service” (NFFS)]. These 
covariates were adopted in previous studies on quality of care provided by physicians.
28-
30
 The remuneration type for each prescriber was determined using physician-specific 
claims to all their patients (i.e., not only limiting to study patients) in the physician-
service file between 365 days prior and 365 days on and after the index date. FFS 
remuneration practitioners were defined by at least 80% of claims coded as the FFS type; 
NFFS remuneration practitioners were defined by at least 80% of claims coded as the 
NFFS type. Over 95% of GP physicians could be categorized into one of the groups using 
this approach.  
Finally, we included a variable identifying patients receiving comprehensive 
continuity of care where the patient’s statin prescriber also: 1) claimed at least one 
comprehensive medical exam on the patient; and 2) had the highest number of service 
claims to the study patient compared to all other GPs. We found that this measure of 
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continuity of care is superior to traditional approaches (unpublished). The comprehensive 
continuity of care was estimated during the 365 days after the index date (inclusive). 
Statistical analysis 
The prevalence of age and sex concordance was described using percentages, 
medians and the interquartile range (IQR), as appropriate. Since age concordance was 
strongly influenced by patient age, we stratified the cohort based on age (> 65 years, or 
≤65 years, respectively).  
For each of the concordance variables under analysis (age concordance, sex 
concordance, and age-sex combined concordance), we fit univariate logistic regression 
models using optimal adherence (PDC ≥80%) as the dependent variable. Generalized 
estimating equations (GEE) were used to account for the clustering of patients within 
prescribers in all univariate and multivariable models.
31
 GEE models using different 
types of working covariance matrices were compared and the one with the smallest quasi-
Akaike's information criterion (QAIC) statistic was selected as the final model. Odds 
ratios (ORs) and 95% confidence intervals (95% CI) for the concordance variables were 
obtained from the robust estimators.  
Next, we estimated adjusted effects of the concordance variables using 
multivariable logistic regression models that included patient and prescriber-related 
covariates. Multicollinearity between a concordance variable and each covariate was 
examined using the variance inflation factor (VIF) derived from a regression model. If 
the VIF value was greater than 2.5, the covariate was removed. Two multivariable 
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models were constructed; one included both of the age concordance and sex concordance 
variables, while the second included the age-sex combined concordance variable.  
Age concordance with prescribers was uncommon for patients over 65 years of 
age; therefore, due to the potential bias associated with disproportionately high number of 
elderly patients in the discordant (vs concordant) age group, all adjusted models were 
tested in a subgroup of patients age at or below 65 years. 
In sensitivity analyses, we changed age concordance to 10 years (i.e., instead of 
five) and we modified the threshold of optimal adherence to PDC ≥70%, and PDC ≥90%. 
In addition, we examined the effect of sex concordance within stratified groups based on 
the statin prescribers’ sex. For each prescriber sex group, we reported the proportion of 
patients achieving optimal adherence. We also repeated the analysis of sex concordance 
among the entire cohort of statin users (i.e., not just those ≤65).  
SAS statistical software, version 9.4, (SAS Institute Inc., Cary, NC, USA) was 
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Between January 1, 2012, and December 31, 2017, 180,010 patients received 
statin medications. Among them, 21,149 were excluded for missing demographic 
information, age < 18 on the index date, or lacking continuous beneficiary status. Of the 
58,549 patients who were defined as new statin users, 3,405 (5.8%) were excluded for 
admission to a long term care facility, staying in an out-of-province hospital, 
pregnancy/delivery, or having zero service claims by a GP within the follow-up period. 
Further, 3,270 (5.5%) patients were excluded for having a statin prescriber with missing 
birth year, sex, or remuneration type. The final cohort was comprised of 51,874 new 
users of statin medications [Figure 3.1].  
Initially 1,789 GPs had been identified as statin prescribers for at least one new 
statin user. Among them, 227 (12.7%) prescribers were excluded for missing data on year 
of birth, sex, or undetermined remuneration type. Thus, 1,562 statin prescribers remained 
in the study, and were linked to at least one of the 51,874 patients [Figure 3.1].  
The utility of using statin dispensation claims to identify a single GP prescriber 
was supported by the underlying data. There were 415,564 claims of statin medications 
for the cohort patients within the follow-up period. Most of these claims (85.5%, 
355,206/415,564) originated from GPs who were identified as statin prescribers, while 
only 14.5% (60,358/415,564) from other GPs or specialists. The median number of total 
statin claims per patient during the follow-up period was 9.0 (IQR, 4.0/11.0) and the 
median number of statin claims from the identified prescriber (i.e., the most frequently 
listed GP) was 7.0 (IQR, 3.0/10.0). Other prescribers (e.g., other GPs or specialists) 
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accounted for only 2.0 statin claims per patient (IQR, 1.0/3.0). Moreover, of all patients 
in the cohort, 31,539/51,874 (60.8%) received all statin prescriptions from a single GP 
[Table 3.1].  
The median age of patients on the index date was 59.0 years (IQR, 51.0/67.0), and 
43.9% (22,781/51,874) were females [Table 3.1]. Among the 51,874 patient-prescriber 
pairs, the median age of physicians on the index date was 50.0 (IQR, 40.0/59.0). There 
were 36.0% (562/1,562) female statin prescribers and they appeared in 13,532 (26.1%) 
patient-prescriber pairs [Table 3.1].  
The median age of patients was 10 years older than the median age of prescribers 
(IQR, -3/22 years). Age differences were higher among patients over 65 (median 
difference = 25 years, IQR: 15/35 years) versus those ≤ 65 years (median difference = 4 
years, IQR: -7/14 years) [Table 3.1]. Overall, only 20.6% (n=10,710) of the entire cohort 
were concordant by age (i.e., within 5 years) with their statin prescriber on the index date. 
Most of these age concordant patients were 65 years or younger (88.6% or 9,486/10,710). 
Among those older than 65, only 8.0% (1,224/15,233) were age concordant to their statin 
prescribers and 90.5% (13,780 /15,233) were more than five years older [Table 3.1]. Sex 
concordance was observed in 62.8% (32,551/51,874) of patients. Age-sex combined 
concordance was relatively infrequent, observed in only 13.2% (6,856/51,874) of patients 
overall and 16.7% (6,133/36,641) of patients ≤ 65 years. Among those older than 65, 
there were only 4.7% (723/15,233) patients were both age and sex concordant [Table 3.1]. 
In the multivariate models, the GEE method using the exchangeable working 
covariance matrix had the smallest QAIC value among the tested structures. Logistic 
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regression analysis did not detect an impact of age concordance on optimal adherence 
[unadjusted OR (uOR) = 1.02, 95%CI 0.96 to 1.08; adjusted OR (aOR) = 1.02, 95%CI 
0.97 to 1.07, Table 3.2]. The odds ratios of sex concordance on optimal adherence were 
uOR = 1.05 (95%CI 1.01 to 1.10), and aOR =1.05 (95%CI 1.00 to 1.11), while the 
impact of age-sex combined concordance was similar to sex concordance only: uOR = 
1.06 (95%CI 0.99 to 1.13), aOR = 1.05 (95%CI 0.99 to 1.12) [Table 3.2]. Results were 
similar when analyses were repeated with age concordance measured by a broader range 
of years (i.e., age ± 10 years) or when changing the optimal adherence threshold to PDC 
≥70%, and PDC ≥90% (data not shown).  
In stratified analyses of patients ≤ 65 years of age, sex concordance appeared to 
have a weak association with optimal adherence for patients with male prescribers (aOR 
= 1.06, 95%CI 1.00 to 1.11, Table 3.2). Optimal adherence was observed in 50.9% 
(8,961/17,601) of male patients with male prescribers versus 49.4% (4,529/ 9,173) of 
female patients with male prescribers [Table 3.3]. When restricting to patients of female 
prescribers the result was similar (aOR = 1.05, 95%CI 0.95 to 1.16). In this subgroup, 
optimal adherence was observed in 49.8% (3,011/6,048) of female patients under female 
prescribers versus 48.3% (1,824/3,779) of male patients under female prescribers [Table 
3.3].  
Within the subgroup of patients > 65 years, sex concordance with male 
prescribers was significantly associated with optimal adherence (aOR = 1.10, 95%CI 1.01 
to 1.19) [Table 3.2]. Optimal adherence was observed in 63.9% (4,127/6,455) of male 
patients with male prescribers versus 60.6% (3,098 /5,113) of female patients with male 
prescribers [Table 3.3]. For patients with a female prescriber, sex concordance was not 
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associated with optimal adherence (aOR = 0.96, 95 %CI 0.81 to 1.13) [Table 3.2]. In this 
group, 60.3% (1,476/2,447) of female patients under female prescribers achieved optimal 
adherence versus 62.5% (761/1,218) of male patients under female prescribers [Table 
3.3].  
When the analysis of sex concordance was repeated among the entire cohort of 
statin users (i.e., not just those ≤ 65 years), results were consistent (aOR = 1.05, 95%CI 
1.00 to 1.10). Sex concordance among the subgroup of patients with male physician 
prescribers was significantly associated with the odds of optimal adherence (aOR = 1.06, 
95%CI 1.02 to 1.11); however, sex concordance was not significantly associated with 
optimal adherence among patients with female physicians (aOR = 1.03, 95%CI 0.94 to 
1.13) [Table 3.2].  
3.5 Discussion 
We performed a population-based study of new statin users and their prescribing 
GPs to test whether age and/or sex concordance influences the odds of optimal adherence. 
Age concordance was relatively infrequent, owing largely to the high percentage of 
patients who were over the age of 65 years. Although patients under the age of 65 were 
much more likely to be of similar age with their prescribing physician, no influence of 
age concordance on the odds of optimal adherence could be detected. In contrast, sex 
concordance between patients and physicians was observed more frequently (62.8% in all 
age groups) and the association with optimal medication adherence was stronger than 
age-concordance, albeit with a non-significant, small effect size. Although we cannot rule 
out the possibility that sex concordance with the prescribing physician may influence 
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adherence of some patients, the impact appears to be small in our cohort. To our 
knowledge, our study is the first to investigate age and sex concordance on medication 
adherence, using population based administrative data, and controlled by a wide range of 
patient- and physician-related covariates. 
The literature suggests that patient-physician concordance on certain demographic 
characteristics may influence medication adherence. It appears that patients exhibiting the 
same race/ethnicity as their physician may be more likely to exhibit optimal adherence, 
presumably because of a more effective relationship and/or increased trust. Schoenthaler 
and colleagues reported that the odds of high adherence among white patients treated by 
white physicians were 27% (OR: 1.27, 95% CI 1.01 to 1.61) higher compared with 
patients receiving care from physicians with different ethnicity.
4
 Traylor and colleagues 
found that Spanish speaking patients treated by Spanish speaking physicians were more 
likely to be adherent to medications compared to Spanish speaking patients treated by 
Non-Spanish speaking physicians (50.6% vs 44.8%, p<0.05).
5
  
A possible association between sex concordance and optimal adherence was 
observed (aOR=1.05, 95% CI 1.00 to 1.11) in the initial analysis of patients ≤ 65 years 
and a consistent finding was produced using the entire cohort of statin users (aOR 1.05, 
95%CI 1.00 to 1.10). Although the absolute impact of sex concordance appeared 
relatively small and it did not reach statistical significance, it should be noted that these 
trends occurred in a health care system where patients are free to choose their GP 
physician. In other words, patients with strong preferences for a same-sex prescriber 
would have likely been disproportionately represented in the sex-concordant group, 
especially in areas where multiple physicians were accessible to patients. Saskatchewan 
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offers a universal health care system where patients are free to choose any general 
practitioner who is accepting new patients. Thus, the weak signal observed in this 
analysis occurred despite a clear bias towards the null effect.  
Our study was not without limitations. First, the administrative data used in this 
study only captures dispensations but not consumption of medications. However, 
administrative data have been widely used in medication adherence research and have 
high validity.
33
 Second, administrative databases do not capture clinical data such as 
disease status, treatment effectiveness, or medication tolerability. Although 
misclassification of non-adherence could occur, it is unlikely to correlate with 
concordance groupings. Third, lack of randomization increases the chance of unmeasured 
confounding between concordance groups. Fourth, the income quintile data from the 
administrative database was old (from the census data of 2006). More recent data should 
be used when it is available in future studies. Fifth, patients above 65 years of age were 
excluded from the analyses of age concordance. However, the issue of age-concordance 
with physicians is not relevant to elderly patients as very few physicians in our cohort 
practiced during their elderly years (i.e., median age of prescribers was 50 years). Finally, 
the impact of concordance was examined in a health care system that allows patients to 
choose their own providers. As discussed above, the direction of the bias is likely towards 
the null.  
3.6 Conclusion 
Age concordance between patients and statin prescribers does not appear to 
impact the odds of optimal adherence. However, a weak signal was detected for a 
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possible effect of sex concordance. Future studies should re-examine the impact of sex-
concordance in areas where provider access is limited or in health systems that limit 





















Number of individuals receiving 
provincial health insurance in 
Saskatchewan  
(January1, 2012 to December 31, 
2017) 
1,370,746 
Dispensed a statin medication 
(January 1, 2012 to December 31, 
2017) 
180,010 patients 
Not dispensed a statin 
86.9% (1,190,736 /1,370,746) 
179,923 
Missing birth/sex information or age < 18  
on the index date
a
 
0.05% (87/ 180,010) 
158,861 
Loss of beneficiary status (including deceased) within 
five years prior to, or one year on or after the index date 
11.7% (21,062/180,010) 
New users of statin medications 
58,549 patients / 1,789 GPs
b 
Not new users, i.e., dispensed of statin within five years 
prior to the index date 
55.7% (100,312/180,010) 
57,761 
Admitted to long term care facilities within five years 
prior to, or one year on or after the index date 
1.3% (788/58,549) 
57,420 
Staying in an out-of-province facility for acute care within 
one year on and after the index date 
0.6% (341 /58,549) 
57,240 
Pregnant/delivery within one year prior to, or one year on 
or after the index date 
0.3% (180/58,549) 
55,144 
No visit to a GP within one year on or after the index 
date, or none of the visited physicians can be identified 
3.6% (2,096/58,549) 
53,131 
Prescribed by a GP missing age or sex data 
3.4% (2,013/58,549) 
51,874 patients / 1,562 GPs 
Prescribed by a GP of unknown remuneration type 
2.1% (1,257/58,549) 








 Total Age≤65 Age > 65  
  n=51,874 n=36,641 n=15,233  
      
Age of patients, median (IQRa)  59.0 (51.0, 67.0) 54.0 (48.0, 60.0) 73.0 (69.0, 79.0)  
Age of prescribersb, median (IQR)  50.0 (40.0, 59.0) 50.0 (40.0, 59.0) 49.0 (40.0, 59.0)  
      
Age difference (patient minus 
prescriber), median (IQR) 
 10.0 (-3.0, 22.0) 4.0 (-7.0, 14.0) 25.0 (15.0, 35.0)  
      
Age concordancec, n (%)  10,710 (20.6) 9,486 (25.9) 1,224 (8.0)  
Age discordanced      
Patients > 5 years younger 
than prescribers, n (%) 
 10,804 (20.8) 10,575 (28.9) 229 (1.5)  
Patients >5 years older than 
prescribers, n (%) 
 30,360 (58.5) 16,580 (45.2) 13,780 (90.5)  
      
Female patients, n (%)  22,781 (43.9) 15,221 (41.5) 7,560 (49.6)  
Female prescribers/prescribers of all 
sex, n (%) 
 
 562/1,562 (36.0) 545/1,495 (36.5) 465/1,309 (35.5)  
Patients whose statin prescribed by a 
female GPe, n (%) 
 
 13,532 (26.1) 9,867 (26.9) 3,665 (24.1)  
Sex concordance, n (%)  32,551 (62.8) 23,649 (64.5) 8,902 (58.4)  
Age-sex combined concordance, n (%)  6,856 (13.2) 6,133 (16.7) 723 (4.7)  
Statin claims per patient, median (IQR)  9.0 (4.0, 11.0) 9.0 (4.0, 11.0) 10.0(5.0, 12.0)  
Statin prescribers per patient,  
median (IQR) 
 
 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)  
Patients with a unique statin prescriber, 
n (%) 
 
 31,539 (60.8) 23,543 (64.3) 7,996 (52.5)  
Patients with multiple statin 
prescribers, n (%) 
 20,335 (39.2) 13,098 (35.7) 7,237 (47.5)  
      
Statin claims by the paired prescriber,  
median (IQR) 
 
 7.0 (3.0, 10.0) 7.0 (3.0, 10.0) 7.0 (4.0, 11.0)  
Statin claims by other prescribers, 
median (IQR) 
 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)  
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Table 3.1 Baseline characteristics of new statin users (continued). 
aIQR = interquartile range; bAge of individual prescribers was re-calculated for each of their patients on the date of the earliest statin 
dispensation; cAge concordance was defined as patient age falling within five years above or below the prescriber’s age; dAge 
discordance was defined as patient age falling at least five years above or below the prescriber’s age; eGP = general practitioners;  
fCharacteristics measured within 365 days prior to the date of the earliest statin dispensation. 
  
 
 Total age≤65 Age > 65 
  n=51,874 n=36,641 n=15,233 
     
1+ acute care hospitalizationsf, n (%)  
 
 11,493 (22.2) 6,154 (16.8) 5,339 (35.0) 
     
GP visitsf, median (IQR)  6.0 (3.0, 9.0) 5.0 (3.0, 8.0) 7.0 (4.0, 11.0) 
     
Specialist visitsf, median (IQR)  2.0 (0.0, 6.0) 2.0 (0.0, 5.0) 4.0 (1.0, 10.0) 
     
1+ emergency department visitsf, n (%)  10,952 (21.1) 6,789 (18.5) 4,163 (27.3) 
     

























     
Patients living in a rural areaf, n (%)   15,830 (30.5) 10,729 (29.3) 5,101 (33.5) 
     
Charlson comorbidity scoref > 0, n (%)   16,988 (32.7) 9,463 (25.8) 7,525 (49.4) 
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Table 3.2: Odds Ratios (95% confidence intervals) for age and sex concordance with 
optimal adherence proportion of days covered >=80%) among new statin users  
 Unadjusted odds ratio 
(95% confidence interval) 
Adjusted odds ratio
b 
(95% confidence interval) 
Patients aged ≤65 years   
Age concordance
a
 (yes vs no ) 1.02 (0.96, 1.08) 1.02 (0.97, 1.07) 
Sex concordance (yes vs no) 1.05 (1.01, 1.10)
c
 1.05 (1.00, 1.11) 
Patients paired to a 
male prescriber 
1.02(0.97, 1.07) 1.06 (1.00, 1.11) 
Patients paired to a 
female prescriber 
1.15(1.05, 1.27) 1.05 (0.95, 1.16) 
Age-sex combined concordance 1.06 (0.99, 1.13) 1.05 (0.99, 1.12) 
Patients aged > 65 years   
Sex concordance (yes vs no) 1.08(1.00, 1.15) 1.03 (0.94, 1.12) 
Patients paired to a male 
prescriber 
1.12(1.04, 1.21) 1.10 (1.01, 1.19) 
Patients paired to a female 
prescriber 
0.93(0.79, 1.09) 0.96 (0.81, 1.13) 
Patient age ≤65 and > 65   
Sex concordance (yes vs no) 1.03(0.99, 1.07) 1.05 (1.00, 1.10) 
Patients paired to a male 
prescriber 
1.00(0.96,1.05) 1.06 (1.02, 1.11) 
Patients paired to a female 
prescriber 
1.12(1.02,1.22) 1.03 (0.94, 1.13) 
aAge concordance = prescriber and patient age difference within ±5 years (age measured on the patient’s date receiving the first 
dispensation of a statin medication); bAdjusted odds ratios were from models with covariates including: age, sex, residence 
(rural/urban),income quintile based on census area, number of distinct prescription medications, number of out-patient visits (to GPs 
and to specialists, respectively), percentage of prescription medication cost paid by government health insurance, number of 
hospitalizations for acute care, number of emergency department visits, Charlson comorbidity score, clinical conditions (including 
osteoporosis, rheumatoid arthritis, hypertension, stroke, ischemic heart disease, acute myocardial infarction, heart failure, multiple 
sclerosis, Parkinson’s disease, Alzheimer’s disease and dementia, epilepsy, asthma, chronic obstructive pulmonary disease, diabetes, 
mood and anxiety diseases, schizophrenia, and cancer), status of comprehensive continuity of care, prescribers’ age, sex, country of 




Table 3.3: Frequency (%) of adherent patients (having a proportion of days covered 
by statin ≥ 80%) by sex concordance status. 
 Adherent patients  
in the sex concordance
b
 group 
% (adherent patients / total in 
the group) 
Adherent patients  
in the sex discordance
c
 group 




 ≤65 years   
paired to a male 
prescriber 
50.9(8,961/17,601) 49.4(4,529/9,173) 
paired to a female 
prescriber 
49.8(3,011/6,048) 48.3(1,824/3,779) 
Patient age > 65 years   
paired to a male 
prescriber 
63.9(4,127/6,455) 60.6(3,098/5,113) 
paired to a female 
prescriber 
60.3(1,476/2,447) 62.5(761/1,218) 
Patients of all age 
groups 
  
paired to a male 
prescriber 
54.4(13,088/24,056) 53.4(7,627/14,286) 
paired to a female 
prescriber 
52.8(4,487/8,495) 51.7(2,585/4,997) 
aPatient age was measured on the index date (the date receiving the first statin medication);bSex concordance = the patient and the 
prescriber were of the same sex (e.g., a female patient matching to a female prescriber);cSex discordance = the patient and the 
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Background: Physician-prescribers may have a strong influence on patient medication 
adherence but their overall effect has never been quantified.   
Objective: We explored the extent to which the influence of physician-prescribers may 
help explain variance in patient adherence to statin medications.  We further examined 
the association between statin medication adherence and specific components of 
physician-prescriber effects including: a) a ‘latent’ effect (i.e., physician effect 
unexplained by patient and prescriber characteristics); and b) specific prescriber 
characteristics.  
Design: A retrospective cohort study. 
Setting: Population-based health administrative data from Saskatchewan, Canada. 
Participants: Physician prescribers and their patients receiving a new statin medication 
between January 1, 2012 and December 31, 2017.  
Explanatory Variables: Prescriber variables included sex, country of medical training; 
years in practice; remuneration type; number of patients; number of patients taking a 
statin (statin patient count). Patient variables included sex; residence; income; number 
and cost of medications; number of out-patient visits; number of visits to emergency 
departments; hospitalizations; comorbidities; and an indicator of continuity of care. 
Main Outcome Measure(s): Optimal adherence to statin medications (i.e., proportion of 
days covered ≥ 80%) measured at one year after the first statin dispensation. 
Statistical analysis: The overall physician impact on optimal medication adherence (i.e., 
PDC >= 80%) was estimated from the intraclass correlation coefficient (ICC) derived 
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from a random intercept model controlled by numerous patient-level variables (e.g., sex, 
residence, income, etc.). We also measured the impact of unmeasured physician factors 
or latent effects based on the ICC of a random intercept model controlled by both patient 
variables and physician-level factors (e.g., country of medical training, remuneration type, 
statin patient count, etc.).  Finally, we estimated the impact of specific physician-level 
factors [sex, country of medical training, years in practice, remuneration type, number of 
patients, and number of patients taking a statin (statin patient count)]. Unadjusted odds 
ratios (uOR) for each factor were generated from logistic regression models; adjusted 
odds ratios (aORs) were obtained from non-linear mixed-effects logistic regression 
models adjusted by patient-level variables. 
Results: We identified 51,874 new statin users and 1,562 general practitioner (GP) 
prescribers. Overall, 6.4% of the observed variance in optimal adherence could be 
attributed to prescribers (p<0.0001, after adjusting for patient level variables only). 
Prescriber variables associated with higher odds of achieving optimal adherence were: 
medical training in Canada versus abroad [adjusted odds ratio (aOR) = 1.40, 95%CI 1.30 
to 1.51], non-fee-for-service remuneration compared to fee-for-service (aOR = 1.18, 
95%CI 1.08 to 1.29), higher statin patient count (aOR = 1.06, 95%CI 1.03 to 1.09 for 
every additional 100 statin patients), and more years prescribing statin (every additional 
ten years, aOR = 1.30, 95%CI 1.14 to 1.48). Physician variables associated with a lower 
odds of optimal adherence included years in practice (every ten additional years, aOR = 
0.76, 95%CI 0.66 to 0.87), and a higher overall patient count (every 1,000 additional 
patients, aOR = 0.98, 95%CI 0.97 to 1.00). These physician-level characteristics 
explained very little of the overall variance. The majority of prescriber influence (5.2%) 
was attributed to the variance unexplained by patient and prescriber variables (p<0.0001). 
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Conclusions: The overall impact of prescribers on optimal statin adherence appears to be 
very limited. Even “high-performing” physicians face significant levels of sub-optimal 





Poor medication adherence is frequently observed among patients receiving 
chronic medications but specific causal factors remain poorly understood.
1
 Evidence 
suggests that physicians strongly influence adherence through several pathways 
connected to their professional role.
2-13
 Physicians are typically responsible for 
diagnosing the condition,
14





 and providing education and follow-up.
19-22
 In each of these 




The most commonly investigated pathways of physician influence on medication 
adherence have focused on interpersonal skills such as communication and trust, 
2, 3, 5, 10-
12
 as well as practice-related factors such as follow-up visits/organization of care.
6, 7, 9, 13
 
Given the evidence linking these physician-related factors with medication adherence,
2, 3, 
5, 10-12
 it is plausible that highly skilled prescribers would have relatively small numbers of 
patients who exhibit non-adherence.        
The determinants of good communication and trust are not easily defined. 
Communication can be impacted by physician factors such as physician age, sex, years in 
practice, workload, and country of medical training.
25-29
  Some of these physician 
characteristics will change over their career including age, experience, workload, and 
perhaps their ability to influence patient adherence. Also, physicians may influence 
adherence through unknown factors (e.g., physicians’ personality, or attitude) that cannot 
be identified using typical research methods. Although these specific factors may not be 
identifiable, effects on adherence due to unmeasured variables can be detected and 
described as a latent effect.
30
  To our knowledge, a comprehensive evaluation of the 
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impact of physicians on medication adherence has never been conducted at the 
population level. The aim of this study was to determine the extent to which ‘prescriber 
effects’ may help explain variance in patient adherence to statin medications.  We further 
examined ‘prescriber effects’ in two components: a) a ‘latent’ effect (i.e., physician effect 
unexplained by patient and prescriber characteristics); and b) specific prescriber 
characteristics and their association with statin adherence.    
4.3 Methods  
Data sources 
The study was conducted using administrative databases from Saskatchewan, 
Canada, which has a population of approximately 1.1 million,
31
 and a universal health 
care system. These databases, linked by a common encrypted identification number for 
each patient, include the provincial health insurance registry file, the physician service 
claims file, the physician registry file, the hospital discharge abstract database, the 
emergency services file, and prescription drug dispensations files.
32
 The variables and 
data definitions of these files have been described in other studies.
33, 34
 
Study design and population 
We performed a retrospective cohort study of new users of statin medications. 
Inclusion criteria were: at least one dispensation of statin medication and the first statin 
dispensation (based on a five-year washout) between January 1, 2012 and December 31, 
2017; and, age >=18 years old on the date of the earliest dispensation of a statin 
medication (index date). Patients were followed for 365 days. 
 A previous study showed that general practitioner (GP) physicians prescribe over 
85% of the statin mediations used in Saskatchewan.
34
 A single GP physician was 
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assigned as the prescriber to each statin patient based on their statin prescription 
dispensations during the one-year follow-up period (i.e., the GP who prescribed the 
greatest number of statin dispensations, independent of any specialist-prescribed statin 
dispensations). Patients were excluded if: no GP prescribers were listed on their statin 
dispensations; there were missing values for specific variables (age or sex of patient or 
prescriber, country of medical training for prescriber), unable to determine the physician 
remuneration type;
34
 insufficient follow-up (i.e., loss of beneficiary status, deceased, or 
admitted to a long term care facility in the 5 years before, or one year after, the index date; 
hospitalized in an out-of-province acute care facility during the follow-up period; 
pregnancy within one year before or after the index date [International classification of 
diseases codes (ICD) 9
th
 version (ICD-9): 641-676, V27; 10
th
 version (ICD-10) and 10
th
 
revision of Canada (ICD-10-CA): O1, O21-95, O98, O99, Z37].  
Outcome measure 
The study outcome was optimal adherence to statin medications during the first 
year of therapy, defined by the proportion of days covered (PDC) ≥80% using methods 
previously described [Supplementary Appendix A].
23, 24
  Tablets dispensed during early 
refills were allowed to accumulate in the numerator and switching between different 
statin medications was allowed.  
Explanatory variables 
The variables of primary interest were focused characteristics of GP prescribers. 
Both time-invariant and time-varying variables were included [Table 1]. Time-invariant 
physician level variables included sex and country of medical training. Time-varying 
physician level variables included prescriber’s age, years in practice, remuneration type 
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[i.e., fee-for-service (FFS) versus non-fee-for-service (NFFS)], overall patient count (i.e., 
to indicate a GP’s workload),
35, 36
 and statin patient count (i.e., to indicate a GP’s 
experience with statin medications) [Table 1].  
In addition, we included patient level variables that were previously used in 
medication adherence studies to addressing confounding [S-Table 1].
1
 These variables 
were all time-invariant (i.e., did not vary over time), including: age, sex, area of residence 
(i.e., rural/urban
37
); calendar year on index date; neighborhood median household income 
quintiles (lowest=1, highest=5);
38, 39
 number of distinct prescription medication classes;
40
 
number of out-patient visits to GPs and to specialists; percentage of prescription 
medication cost paid by government health insurance; number of hospitalizations for 
acute care; number of emergency department visits; Charlson comorbidity score;
41
 and 
presence or absence of a set of clinical conditions using validated case definitions by the 
Canadian Chronic Disease Surveillance System dating back to January 1
st
, 1996 [S-Table 
1]. We also included an indicator of continuity of care, which was strongly associated 
with medication adherence in a previous study.
33
   
Statistical Analysis 
We described patient and physician characteristics of the cohort. For each GP 
prescriber, we calculated the prevalence of optimal adherence within their statin patient 
group. To compare individual GP physicians, we ranked prescribers into quartiles of 
increasing prevalence of statin adherence and described patient and prescriber 
characteristics within these groups. Between-group differences for median values were 
assessed by the Wilcoxon rank-sum test, and percentages by the Chi-squared test.  
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Next, we quantified the influence of GP prescribers (independent of patient 
characteristics) with multivariable logistic regression analyses using two-level (patient 
and prescriber) non-linear mixed-effects models. We calculated the intraclass correlation 
coefficient (ICC) for prescribers from an empty model (i.e., a model with the random 
intercept only), a model that also included patient level variables, and a model that also 
both patient and physician level variables.
30
  The intraclass correlation estimates the 
proportion of the total variance in patient adherence accounted for by the clustering of 
patients within physicians.  
The effects of the prescriber level variables on optimal adherence were expressed 
as unadjusted (u) or adjusted (a) odds ratios (OR) and 95% confidence intervals (95% 
CIs). The unadjusted effect of each explanatory variable was examined in univariate 
logistic regression models (i.e., without a random intercept term). The adjusted effects of 
these variables were examined in multilevel multivariable logistic regression models with 
all patient and prescriber related variables.  
Several models were constructed beginning with an empty model (i.e., without the 
random intercept term or explanatory variables), and adding the prescriber identification 
numbers (i.e., a random intercept term), then all patient-level variables sequentially [after 
excluding those exhibiting multicollinearity with any of the physician-level factors 
defined as variance inflation factor (VIF) > 2.5].
42
  The likelihood ratio test (LRT) was 
applied in each step to determine whether the additional terms significantly improved 
model fit.
43
    
Next, we added physician-level characteristics into the model containing the 
random intercept and patient variables.  Each physician variable of interest was added 





For time-varying, physician-level variables, we evaluated multiple possible components 
including a contextual effect (between prescribers), a compositional effect (between 
patients within a prescriber), a random slope (the compositional effect varying between 
prescribers), and between/within level interactions.
43
  The mean centering method was 




   
Our initial modelling results indicated that prescriber age and prescriber years in 
practice were highly correlated.  Prescriber age was excluded from all models after an 
analysis suggesting it did not interact with the effects of years in practice [Supplementary 
Appendix B]. Also, we found contradictory effects in the prescriber years in practice 
variable after decomposition.  The between-prescriber analysis suggested that the odds of 
optimal adherence was lower for prescribers with longer years in practice while the 
within-prescriber estimate indicated the odds of optimal adherence improved during this 
time. This apparent contradiction was clarified by calculating a dispersion statistic to 
clarify the within-prescriber result (Supplementary Appendix C). To illustrate the impact 
of dispersion on the modelling results for optimal adherence, we contrasted the mean 
years in practice with the dispersion (or standard deviation of years in practice).  SAS 
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We identified 58,549 patients who initiated statin therapy between January 1, 
2012, and December 31, 2017. Among them, 3,405 (5.8%) were excluded for residing in 
a long-term care setting, hospitalized in an out-of-province facility, pregnancy, or having 
no service claims by a GP within the follow-up period. Also, 3,270 (5.5%) patients were 
excluded because their statin prescriber was missing data on birth, sex, graduation, or 
remuneration type. Thus, 51,874 new users were included in the final cohort. These 
patients were paired to 1,562 statin prescribers [Figure 4.1]. The mean age of patients on 
the index date was 59.0 years (IQR 51.0/67.0) and 43.9% were female. Among the 
patients, 15,830 (30.5%) lived in a rural area, 16,988 (32.7%) had a Charlson score 
greater than 0, and 11,493 (22.2%) received acute care in hospital within 365 days prior 
to the index date. Of the prescriber-patient pairs, the mean age of the prescribers was 50.0 
years (IQR 40.0/49.0), 26.1% (n=13,532) were paired to a female prescriber, and 29.8% 
(n=15,462) were with a prescriber receiving their medical training in Canada. Prescribers 
had a median overall patient count of 3,346 (IQR 2,203/5,453), and a median statin 
patient count of 276 (IQR 177/413). The median number of study patients (new statin 
users) per prescriber was 16 [IQR <6 (value suppressed due to small cell size)/43].  
The median prevalence of optimal statin adherence within prescriber groups was 
52.4% (IQR 35.7%/65.5%). After ranking prescribers into quartiles based on increasing 
prevalence of statin adherence, clear differences in patient characteristics were observed 
between physician groups [Table 4.2]. Prescribers in the highest quartile (i.e., with the 
highest prevalence of optimal adherence among their patients) had patients who were 
older (median age = 61.0 IQR 54.0/70.0 vs 55.0 IQR 47.0/64.0, p<0.0001), less likely to 
be female (39.9% vs 47.4%, p<0.001), more likely to have a previous hospitalization for 
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acute care (39.4% vs 16.4%, p<0.001) or emergency room visit (30.1% vs 19.9%, 
p<0.001), more visits to a specialist (median =4.0 IQR 1.0/10.0 vs median=2.0 IQR 
0.0/5.0, p<0.0001), and more with a Charlson score greater than 0 compared to 
physicians in the lowest quartile (46.4% vs 26.9%, p<0.001). Prescriber characteristics 
also differed across these quartiles. Prescribers in the highest quartile were less likely to 
be females (21.9% vs 27.9%, p<0.0001), more likely to be trained in Canada (55.7% vs 
12.2%, p<0.001), less likely to be a NFFS prescriber (14.0% vs 17.9%, p<0.001), and 
prescribed statins more often (median statin patient count=253 IQR 176/334 vs 210, IQR 
116/350, p<0.0001) compared to prescribers in the lowest quartile [Table 4.2]. 
The random intercept model (without patient and prescriber variables) was 
significantly different from the empty model without random terms (p<0.0001). The ICC 
derived from the random intercept model was 8.1%. Based on the ICC from the model 
that included patient level variables, individual physicians accounted for 6.4% of the total 
variance in optimal adherence observed in the population (reduced by 21.0% from the 
random intercept model, p < 0.0001).  
A GP prescriber’s country of medical training was significantly associated with 
their patient’s odds of optimal statin adherence (Canada vs foreign, uOR=1.53, 95%CI 
1.47 to 1.59; aOR=1.40, 95%CI 1.30 to 1.51). However, on inspection of the patient 
characteristics between these prescribers (36,422 prescribed by foreign-trained GPs vs 
15,452 by Canadian-trained GPs) several differences were observed. Patients prescribed 
statins by foreign trained GPs were more frequently living in rural areas (32.4% vs 26.1%, 
p<0.001), with a substantially lower incidence of prior hospitalizations (18.1% vs 31.8%, 
p<0.0001), fewer emergency department visits (17.5% vs 29.7%, p<0.0001), and fewer 
99 
 
with a Charlson score greater than 0 (i.e., score >1 = 29.0% vs 41.7%, p<0.001) [Table 
4.3].  
A similar finding was observed for prescribers classified as receiving a NFFS 
(versus FFS) remuneration type. In the adjusted analysis, NFFS was significantly 
associated with an increased odds of optimal adherence (aOR=1.18, 95%CI 1.08 to 1.29); 
however, the unadjusted estimate suggested the opposite effect (uOR = 0.94, 95%CI 0.90 
to 0.99). Again, this variable appeared highly confounded when examining patient 
characteristics as well as the distribution of patients between these two types of 
prescribers (7,849 statin patients prescribed by NFFS GPs vs 44,025 by FFS GPs). 
Patients prescribed statins by NFFS GPs were more often living in a rural area (47.6% vs 
27.5%, p<0.0001), less likely to have been hospitalized previously (17.5% vs 23.0%, 
p<0.0001) or having visited an emergency department (14.8% vs 22.2%, p<0.0001), and 
fewer having a Charlson score greater than 0 (26.4% vs 33.9%%, p<0.0001). Further, 
NFFS prescribers had fewer years in practice (median =15.0, IQR 9.0/27.0 vs 25.0, IQR 
15.0/34.0%, p<0.0001), and lower overall patient counts (median =2,112, IQR 1,567/ 
2,800 vs 3,720, IQR 2409.0/5,823.0%, p<0.0001) [Table 4.3]. 
The overall effect of the GP prescriber’s years in practice was not significantly 
associated with optimal adherence (i.e., per ten additional years in practice: uOR= 0.98, 
95%CI 0.96 to 0.99; aOR = 0.98, 95%CI 0.96 to 1.01). However, as described in the 
methods, decomposition of the overall effect into the between-prescriber effect (i.e., per 
ten additional years in practice: aOR=0.76, 95% CI 0.66 to 0.87) and the within-
prescriber effect (per ten additional years in practice: aOR= 1.30, 95%CI 1.14 to 1.48) 
appeared to be contradictory. Additional analyses using dispersion to represent the 
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within-prescriber effect confirmed the existence of these two effects simultaneously 
[Supplementary Appendix C].   
Finally, a small but positive association was observed with an increasing number 
of patients receiving statins from a GP prescriber (i.e., for every additional 100 statin 
patients uOR=1.01, 95%CI 1.00 to 1.02; aOR=1.06, 95%CI 1.03 to 1.09), while the total 
patient count of a prescriber (i.e., representing workload) showed a very slight negative 
association with the odds of achieving optimal adherence (i.e., for 1000 additional 
patients uOR = 0.98, 95%CI 0.98 to 0.99; aOR=0.98, 95%CI 0.97 to 1.00). Prescriber sex 
was not significantly associated with patients’ adherence outcomes (uOR=0.93, 95%CI 
0.90 to 0.97; aOR= 0.99, 95%CI 0.91 to 1.07) [Table 4.4]. After accounting for all patient 
and prescriber variables, the prescriber latent effect accounted for only 5.2% of the 
variance in optimal adherence among the study population (reduced by 18.8% from the 
overall prescriber variance, p<0.0001). 
4.5 Discussion 
In this population-based study, we examined the impact of GP prescribers on 
patient adherence to statin medications. When prescribers were ranked into quartiles 
based on the prevalence of optimal adherence among their patients, several notable 
observations were evident. First, the upper quartile boundary of optimal adherence was 
only 65.4%. In other words, it appeared that “performance” on medication adherence was 
not skewed and many of the highest ‘performing’ prescribers still failed to motivate 
optimal adherence in up to one-third of their patients. Furthermore, differences between 
the highest and lowest ranking prescribers included clear trends in the characteristics of 
their patients. Prescribers with the highest prevalence of optimal adherence cared for 
patients who were older, sicker, and more likely to include a specialist in their care. 
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Indeed, after controlling for differences in patient characteristics, individual GP 
prescribers only accounted for 6.4% of the variance in optimal adherence observed in the 
study population. In contrast to the extensive body of research linking optimal adherence 
to prescriber characteristics such as superior communication skills,
2, 3, 5, 10-12
 our results 
indicate that physicians do not consistently impact statin medication adherence.   
Published associations between high adherence and physician skills such as 
communication may have been a result of reverse causality bias, where adherent patients 
were more likely to rate their physician highly (i.e., for communication or trustworthiness) 
while non-adherent patient may rate the same physician poorly on these same 
characteristics.     
Among physician-level factors associated with optimal adherence, estimates for 
country of medical training and prescriber remuneration appeared to be influenced by 
bias. The effect estimate for country of medical training indicated a significantly higher 
odds of optimal adherence among prescribers trained in Canada. However, we found that 
the patient populations prescribed statins by foreign graduated GPs were more often 
living in rural areas with lower levels of comorbidity/illness (i.e., fewer hospitalizations 
or emergency department visits, and lower Charlson score). These differences in 
measured confounders suggest the possibility of unmeasured factors contributing to the 
observed association with medical training. Further study of these latent variables is 
warranted to understand the true causes underlying this association.  
A similar result was discovered during the assessment of prescriber remuneration 
type. We found that GP prescribers  in a NFFS practice increased their patients’ odds of 
achieving optimal adherence Although this finding aligns with the theory that NFFS 





 we found evidence for bias in our effect estimate. Not only were the 
number of NFFS practitioners far lower than those with FFS remuneration, the types of 
patients receiving statins from these groups of prescribers were different also.  Patients 
receiving care from NFFS prescribers were highly skewed towards living in rural areas 
with lower levels of comorbidity. As a result, it appears the distribution of NFFS 
prescribers in our province is not adequate to allow non-randomized evaluation without 
substantial uncertainty due to the role of bias. Further study is needed to quantify the 
benefits and weaknesses of NFFS remuneration models as a specific focus; quantitative 
evidence for the impact of remuneration models is lacking.
48-50
  
The impact of a prescriber’s years in practice was complex but decomposition 
revealed important findings. The absolute number of years in practice had a significant, 
albeit relatively small negative impact on a prescriber’s ability to influence optimal 
adherence. In a systematic review of 62 studies between 1966 and 2004 by Choudhry and 
colleagues, 32 (52%) studies reported that clinical knowledge, adherence to diagnosis and 
treatment guidelines, and patient health outcome declined as years in practice increased.
25
 
However, our analysis of the within-prescriber effect suggested that the activity of 
prescribing statins throughout the years of practice was also an important factor. 
Specifically, GPs prescribing to new statin patients across multiple years tended to have 
more adherent patients than GPs who had initiated statin treatment for patients over fewer 
years. We also found that the absolute number of statin patients under a GP prescriber’s 
care was associated with a higher odds of optimal adherence. These findings demonstrate 
the difference between the absolute impact of years in practice versus the influence of 
continued activity with statins during those years of practice. It is plausible that frequent 
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prescribing of statin medications throughout the course of a prescriber’s career would 
improve the skills and experience in supporting patients receiving these medications.    
Our study had limitations. First, we only captured dispensations but not 
consumption of statins. However, dispensation data have been widely used to estimate 
medication adherence with high validity.
51
 Second, lack of randomization limited our 
control over unmeasured confounding. This limitation appeared to be especially 
problematic for assessments of remuneration type and country of medical training. Devlin 
and colleagues reported that physicians may self-select into a remuneration type due to 
uncaptured personal preference and characteristics.
52
 The effect of remuneration type and 
graduate country on medication adherence should be examined in future studies in order 
to improve our understanding of these factors. Other unmeasured factors included 
perception of risk, communication style of provider, race/ethnicity concordance, patient-
physician trust level, and conflicting medication information. These variables were not 
captured in administrative data and should be included in future studies when data is 
available. Finally, the impact of calendar year was a possible confounder in our analysis 
as adherence to many chronic medications has been increasing for years.
53
 However, it is 
highly correlated to years in practice, and was excluded in this study.  
4.6 Conclusion 
Physicians have been identified as playing an important role in influencing 
medication adherence among their patients. Although our results confirm that physicians 
play a role, their overall impact on the odds of achieving optimal adherence is very 
limited. Even “high-performing” physicians face significant levels of sub-optimal 
adherence among their patients. Moreover, the ability to partition the physician effect to 
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examine important factors such as remuneration strategy is limited because of system-
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Number of individuals receiving 
provincial health insurance in 
Saskatchewan  
(January1, 2012 to December 31, 
2017) 
1,370,746 
Dispensed a statin medication 
(January 1, 2012 to December 31, 
2017) 
180,010 patients 
Not dispensed a statin 
86.9% (1,190,736 /1,370,746) 
179,923 
Missing birth/sex information or age < 18  
on the index date
a
 
0.05% (87/ 180,010) 
158,861 
Loss of beneficiary status (including deceased) within 
five years prior to, or one year on or after the index date 
11.7% (21,062/180,010) 
New users of statin medications 
58,549 patients / 1,789 GPs
b 
Not new users, i.e., dispensed of statin within five years 
prior to the index date 
55.7% (100,312/180,010) 
57,761 
Admitted to long term care facilities within five years 
prior to, or one year on or after the index date 
1.3% (788/58,549) 
57,420 
Staying in an out-of-province facility for acute care within 
one year on and after the index date 
0.6% (341 /58,549) 
57,240 
Pregnant/delivery within one year prior to, or one year on 
or after the index date 
0.3% (180/58,549) 
55,144 
No visit to a GP within one year on or after the index 
date, or none of the visited physicians can be identified 
3.6% (2,096/58,549) 
53,131 
Prescribed by a GP missing age or sex data 
3.4% (2,013/58,549) 
51,874 patients / 1,562 GPs 
Prescribed by a GP of unknown remuneration type 
2.1% (1,257/58,549) 




Table 4.1: Definitions of variables used to describe physician prescribers. 
 
Variable Levels Description Type of measurement 
Prescriber’s 
sex 









Country of medical training listed in the 




Years Prescriber’s age on the date of each patent’s 






Years Number of years between a statin 
prescriber’s year of medical graduation and a 






(FFS) / Non 
fee-for-service 
(NFFS) 
Derived from all billing claims submitted by 
the prescriber (i.e., not only limiting to study 
patients) between 365 days before and 365 
days after the index date of a patient. If at 
least 80% of these records were coded as 
FFS claims, the prescriber was deemed a 
FFS physician for that specific patient. 
Alternatively, if at least 80% were coded as 
NFFS claims, the prescriber was deemed a 
NFFS physician. Over 95% of GP 
prescribers could be categorized into one of 








The number of patients receiving at least one 
billing claim based on all claims submitted 
by the prescriber (i.e., not only limiting to 
study patients) between 365 days before and 







The number of patients with at least one 
statin dispensation from the GP prescriber. 
(time-varying) between 365 days before and 






Table 4.2: Patient and prescriber characteristics. 
Characteristic Total (all patients) Prescriber Quartile 1 
(% of patients with optimal 
statin adherence  
<35.7%) 
Prescriber Quartile 2 
(% of patients with optimal 
statin adherence 
35.7% to 52.2%) 
Prescriber Quartile 3 
(% of patients with optimal 
statin adherence 
52.3% to 65.4%) 
Prescriber Quartile 4 















% of patients with optimal adherencea  53.6   25.5   45.3   57.8   72.5  
Patient characteristics 
 
      
Age, median (IQRb) 59.0 (51.0, 67.0) 55.0 (47.0, 64.0) 58.0 (50.0, 66.0) 59.0 (52.0, 68.0) 61.0 (54.0, 70.0) 
Females, n(%) 22,781 (43.9) 2,966 (47.4) 6,669 (45.6) 8,669 (43.9) 4,477 (39.9) 
1+ hospitalizations for acute care, n(%) 11,493 (22.2) 1,025 (16.4) 2,284 (15.6) 3,765 (19.1) 4,419 (39.4) 
Visits to GPsc, median(IQR) 6.0 (3.0, 9.0) 6.0 (3.0, 10.0) 5.0 (3.0, 9.0) 6.0 (3.0, 9.0) 5.0 (3.0, 9.0) 
Visits to specialists, median (IQR) 2.0 (0.0, 6.0) 2.0 (0.0, 5.0) 2.0 (0.0, 5.0) 2.0 (0.0, 6.0) 4.0 (1.0, 10.0) 
1+ visits to emergency department, n(%) 10,952 (21.1) 1,243 (19.9) 2,531 (17.3) 3,802 (19.2) 3,376 (30.1) 
Income level, n(%) 
 
      
1 9,569 (18.4) 1,608 (25.7) 2,826 (19.3) 3,275 (16.6) 1,860 (16.6) 
2 9,500 (18.3) 1,224 (19.6) 2,813 (19.2) 3,599 (18.2) 1,864 (16.6) 
3 9,540 (18.4) 1,046 (16.7) 2,675 (18.3) 3,645 (18.4) 2,174 (19.4) 
4 10,685 (20.6) 1,167 (18.7) 2,920 (19.9) 4,222 (21.4) 2,376 (21.2) 
5 9,782 (18.9) 848 (13.6) 2,603 (17.8) 4,032 (20.4) 2,299 (20.5) 
missing 2,798 (5.4) 358 (5.7) 803 (5.5) 987 (5.0) 650 (5.8) 
Rural residence, n(%) 15,830 (30.5) 1,923 (30.8) 4,568 (31.2) 6,173 (31.2) 3,166 (28.2) 
Charlson score > 0, n(%) 16,988 (32.7) 1,683 (26.9) 3,946 (27.0) 6,148 (31.1) 5,211 (46.4) 
Prescriber characteristicsf         
Caseloadd, median (IQR) 16 (<6g, 43) 6 (<6, 14) 21 (7, 49) 33 (17, 67) 10 (<6, 35) 
Age, median (IQR) 50.0 (40.0, 49.0) 55.0 (43.0, 67.0) 48.0 (40.0, 59.0) 49.0 (38.0, 58.0) 50.0 (41.0, 57.0) 
Female, n(%) 13,532 (26.1) 1,746 (27.9) 4,205 (28.7) 5,125 (25.9) 2,456 (21.9) 
Medical training in Canada, n(%) 15,462 (29.8) 765 (12.2) 2,405 (16.4) 6,038 (30.6) 6,254 (55.7) 
NFFSe prescriber, n(%) 7,849 (15.1) 1,122 (17.9) 2,510 (17.1) 2,648 (13.4) 1,569 (14.0) 
Years in practice, median (IQR) 24.0 (13.0, 33.0) 28.0 (16.0, 42.0) 22.0 (13.0, 32.0) 24.0 (12.0, 32.0) 25.0 (15.0, 32.0) 
Overall patient count, median (IQR) 3,346 (2,203, 5,453) 3,535 (2,080, 5,745) 3,313 (2,217, 5,491.5) 3,273.5 (2,249.5, 5,362.5) 3,390 (2,120, 5,474) 
Statin patient count, median (IQR) 276 (177, 413) 210 (116, 350) 289 (170, 418) 309 (206, 458) 253 (176, 334) 
aOptimal adherence = proportion of days covered >=80% of statin medications; bIQR = interquartile range; cGP = general practitioners; dCaseload = number of study patient (new statin users) per 
prescriber; eNFFS = non-fee-for-service remuneration type; findex date = patient’s first statin dispensation date; g<6: actual number of patients was suppressed as there were less than six patients in 
the group. Patient and physician characteristics measured within 365 days prior to the date of the first dispensation of a statin (index date), or on the index date, except that overall patient count, and 
statin patient count were measured within 365 days prior to and 365 days on and after the index date.  
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Table 4.3: Patient and prescriber characteristics stratified by prescriber’s country of medical training and remuneration type. 
Characteristics Total  Prescriber country of medical training Prescriber remuneration type 
 
  Canada Foreign NFFS FFSf 
Patients(n) n=51,874 n=15,452 n=36,422 n=7,849 n=44,025 
Prescribers (n) n=1,562         
Caseloada, median (IQRb) 16 (<6, 43)         
% of patients with optimal adherencec 53.6 60.9 50.5 52.3 53.8 
Patient characteristics 
 
        
Age, median (IQR) 59.0 (51.0, 67.0) 60.0 (52.0, 69.0) 58.0 (50.0, 67.0) 59.0 (52.0, 68.0) 59.0 (51.0, 67.0) 
Females, n(%) 22,781 (43.9) 6,612 (42.8) 16,169 (44.4) 3,536 (45.1) 19,245 (43.7) 
1+ hospitalizations for acute care, n(%) 11,493 (22.2) 4,911 (31.8) 6,582 (18.1) 1,370 (17.5) 10,123 (23.0) 
Visits to GPsd, median(IQR) 6.0 (3.0, 9.0) 6.0 (3.0, 9.0) 6.0 (3.0, 9.0) 5.0 (3.0, 9.0) 6.0 (3.0, 9.0) 
Visits to specialists, median (IQR) 2.0 (0.0, 6.0) 3.0 (1.0, 9.0) 2.0 (0.0, 5.0) 1.0 (0.0, 5.0) 2.0 (1.0, 7.0) 
1+ visits to emergency department, n(%) 10,952 (21.1) 4,591 (29.7) 6,361 (17.5) 1,159 (14.8) 9,793 (22.2) 
Income level, n(%) 
 
        
1 9,569 (18.4) 2,763 (17.9) 6,806 (18.7) 1,766 (22.5) 7,803 (17.7) 
2 9,500 (18.3) 2,678 (17.3) 6,822 (18.7) 1,649 (21.0) 7,851 (17.8) 
3 9,540 (18.4) 2,949 (19.1) 6,591 (18.1) 1,262 (16.1) 8,278 (18.8) 
4 10,685 (20.6) 3,181 (20.6) 7,504 (20.6) 1,672 (21.3) 9,013 (20.5) 
5 9,782 (18.9) 3,098 (20.0) 6,684 (18.4) 1,133 (14.4) 8,649 (19.6) 
missing 2,798 (5.4) 793 (5.1) 2,005 (5.5) 367 (4.7) 2,431 (5.5) 
Rural residence, n(%)f 15,830 (30.5) 4,043 (26.1) 11,787 (32.4) 3,735 (47.6) 12,095 (27.5) 
Charlson score > 0, n(%) 16,988 (32.7) 6,444 (41.7) 10,544 (29.0) 2,073 (26.4) 14,915 (33.9) 
Prescribers charactersticsg            
Age, median (IQR) 50.0 (40.0, 49.0) 49.0 (38.0, 59.0) 50.0 (41.0, 59.0) 41.0 (35.0, 53.0) 51.0 (41.0, 60.0) 
Female, n(%) 13,532 (26.1) 5,006 (32.4) 8,526 (23.4) 3,012 (38.4) 10,520 (23.9) 
Medical training in Canada, n(%) 15,462 (29.8)     1,868 (23.8) 13,594 (30.9) 
NFFSe prescriber, n(%) 7,849 (15.1) 1,868 (12.1) 5,981 (16.4)     
Years in practice, median (IQR) 24.0 (13.0, 33.0) 21.0 (10.0, 33.0) 24.0 (14.0, 33.0) 15.0 (9.0, 27.0) 25.0 (15.0, 34.0) 
Overall patient count, median (IQR) 3,346 (2,203, 5,453) 3,163 (2,022, 4,967) 3,448 (2,285, 5,619) 2,112 (1,567, 2,800) 3,720 (2,409, 5,823) 
Statin patient count, median (IQR) 276 (177, 413) 237 (147, 329) 303 (188, 440) 176 (120, 250) 301 (200, 438) 
aCaseload = number of study patients (new statin users) per prescriber; ; bIQR = interquartile range; cOptimal adherence = proportion of days covered >=80% of statin medications; dGP = general 
practitioners; eNFFS = non-fee-for-service remuneration type; fFFS= fee-for-service remuneration type; fRural residence = living in areas of a population under 1,000;gindex date = the date of the 
first dispensation of a statin medication. 
Patient and physician characteristics measured within 365 days prior to the date of the first dispensation of a statin (index date), or on the index date, except that overall patient count, and statin 
patient count were measured within 365 days prior to and 365 days on and after the index date.  
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Table 4.4: Odds ratios (95% confidence interval) for the association of prescriber-
related characteristics with optimal statin adherence (proportion of days covered by 


















Country of medical 
training  
(Canada vs foreign) 
1.53 (1.47, 1.59)
e
 1.40 (1.30, 1.51) 
  
Sex  
(female vs male) 
0.93 (0.90, 0.97) 0.99 (0.91, 1.07) 
  
Years in practice  
(per 10 years increase) 
0.98 (0.97, 0.99) 0.76 (0.66, 0.87) 1.30 (1.14, 1.48) 1.30 (1.26, 1.35) 




0.94 (0.90, 0.99) 1.18 (1.08, 1.29) 1.23 (0.91, 1.66) 
 
Overall patient count  
(per 1,000 increase) 
0.98 (0.98, 0.99) 0.98 (0.97, 1.00) 0.99 (0.96, 1.01) 
 
Statin patient count  
(per 100 increase) 
1.01 (1.00, 1.02) 1.06 (1.03, 1.09) 1.02 (0.97, 1.06)   
aCountry of medical training and sex were measured on the date of the first dispensation of a statin (index date), overall patient count 
and statin patient count measured on 365 days prior and 365 days on and after the index date;bNFFS = non-fee-for-service 
remuneration method, FFS = fee-for-service remuneration method;c95%CI = 95% confidence interval; dAdjusted for patient variables 
including age, sex, urban/rural living, household income level, number of medications by the anatomical therapeutic chemical (ATC) 
class, number of outpatient visits, percentage of medication cost paid by government health insurance, number of hospitalization for 
acute care, number of visits to emergency department, Charlson comorbidity score, clinical conditions (osteoporosis, rheumatoid 
arthritis, hypertension, stroke, ischemic heart disease, acute myocardial infarction, heart failure, multiple sclerosis, Parkinson’s disease, 
Alzheimer’s disease and dementia, epilepsy, asthma, chronic obstructive pulmonary disease, diabetes, mood and anxiety diseases, 






4.8 Supplementary materials 
Appendix A: Measure of medication adherence outcome. 
The study outcome was optimal adherence to statin medications during the first 
year of therapy, defined by the proportion of days covered (PDC) ≥80%.
1, 2
 The PDC was 
estimated using the sum of the number of tablets dispensed (assuming one tablet per day 
dosing) divided by the number of days in the follow up period (365 days minus the 
number of days spent in a hospital for acute care because hospital drug dispensations are 
not captured).
3
 Tablets dispensed during early refills were allowed to accumulate in the 




S-Table 1: Patient level factors used to control confounding in the assessment of 
physicians’ influence on statin medication adherence.   
Variable Levels Description 
Age Years Years since birth to the index date (i.e., the date of the earliest 
statin dispensation). 
Sex Male/female -  
Area of residence Rural/urban Rural area defined as a population under 1,000 based on 
linkage between residential postal code and national census 
data. 
Household income Quintiles Calculated as the mean of the neighborhood mean based on 
linkage between residential dissemination area code and 
national census data. 
Number of distinct 
prescription 
medications 
Continuous Defined by anatomical therapeutic chemical classification 
(ATC) level-5 classes, and measured within 365 days prior to 
the index date. 
Number of out-
patient visits to 
GPs  
Number Number of out-patient visits to physicians who were identified 
as general practitioners (GPs) within 365 days prior to the 
index date. 
Number of out-
patient visits to 
specialists 
Number Number of out-patient visits to physicians who were identified 





Number Proportion of spending on prescription medications paid by 




for acute care  
Number Number of hospitalizations for acute care within 365 days 
prior to the index date. 
Emergency 
department visits 
Number Number of visits to emergency department within 365 days 
prior to the index date. 
Charlson 
comorbidity score  
0, 1-2, 3, >3 Charlson comorbidity index score
4
 measured within 365 days 
prior to the index date.  
Continuity of care Yes/No Having the same general practitioner (GP) as the most 
frequently visited GP, the most frequent prescriber of statin, 
and the complete medical examination provider within 365 
days on and after the index date. 
Calendar year of 
cohort entry  
2012, 2013, 2014, 
2015, 2016, 2017 
Calendar year of the index date (excluded in statistical models 
as having multicollinearity to prescriber-related variable 
‘years in practice’) 
Chronic 
conditions  
Yes/No Including osteoporosis, rheumatoid arthritis, hypertension, 
stroke, ischemic heart disease, acute myocardial infarction, 
heart failure, multiple sclerosis, Parkinson’s disease, 
Alzheimer’s disease and dementia, epilepsy, asthma, chronic 
obstructive pulmonary disease, diabetes, mood and anxiety 
diseases, schizophrenia, and cancer. 
The diagnostic codes and algorithm of these clinical 
conditions are summarized in a table published by CCDSS.
5
 





Appendix B: Analysis of prescriber years in practice and prescriber age. 
The components of prescriber years in practice were associated with optimal 
medication adherence as described in the main manuscript.  However, we excluded 
prescriber age in this model because of a strong correlation with prescriber years in 
practice.  As a result, we assessed the extent to which prescriber age may have 
confounded the association between years in practice and adherence to ensure our 
reported estimates were valid. 
To examine the potential confounding by prescriber age, we repeated the analysis 
of prescriber years in practice within patient strata according to their prescribers’ median 
age. A prescriber’s media age was calculated according to the prescriber’s age on index 
dates of paired patients (30-39, 40-49, 50-59, and 60-69).  
The within-prescriber effects on years in practice among patient groups stratified 
by prescriber’s age were consistent with the effect of the whole cohort [prescriber age 30 
to 39: aOR = 1.18(0.88, 1.59), 40 to 49: 1.48(1.14, 1.91), 50 to 59: 1.28(1. 24, 1.60), and 
60 to 69: 1.46(1.02, 2.09), Appendix table 2]. Similarly, the between-prescriber effects 
were also consistent with the overall analysis in that the estimated odds of achieving 
optimal adherence declined with additional years in practice.  Of note, the odds ratio 
estimates were only significant for strata where prescribers’ age was under 50 [prescriber 




S-Table 2: Odds ratios (95% confidence interval) for the association of every 10 
more years in practice with optimal statin adherence stratified by prescriber’s age. 









Between prescribers Within a prescriber 
30 to 39 11,815/452 0.66 (0.45 to 0.98)
c
 1.18 (0.88, 1.59) 
40 to 49 12,964/400 0.73 (0.55, 0.98) 1.48 (1.14, 1.91) 
50 to 59 13,985/299 0.89 (0.67, 1.18) 1.28 (1.24, 1.60) 
60 to 69 9,086/215 0.90 (0.59, 1.39) 1.46 (1.02, 2.09) 
 
aPrescriber’s age = prescriber median age of a prescriber’s patients on the index date (date the first statin was 
dispensed); bAdjusted for patient variables including age, sex, urban/rural living, household income level, number of 
medications by the anatomical therapeutic chemical (ATC) class, number of outpatient visits, percentage of medication 
cost paid by government health insurance, number of hospitalization for acute care, number of visits to emergency 
department, Charlson comorbidity score, clinical conditions (osteoporosis, rheumatoid arthritis, hypertension, stroke, 
ischemic heart disease, acute myocardial infarction, heart failure, multiple sclerosis, Parkinson’s disease, Alzheimer’s 
disease and dementia, epilepsy, asthma, chronic obstructive pulmonary disease, diabetes, mood and anxiety diseases, 
schizophrenia, and cancer); also adjusted for prescriber-related variables including prescriber’s sex, country of medical 
training, remuneration type, overall patient count, and statin patient count; cOdds ratios in bold font are statistically 




Appendix C: Analysis of prescriber years in practice (between prescriber effect 
versus within prescriber effect) 
The between-prescriber analysis suggested that the odds of optimal adherence was 
lower for prescribers with longer years in practice while the within-prescriber estimate 
indicated the odds of optimal adherence improved during this time. This apparent 
contradiction was clarified by calculating a dispersion statistic to clarify the within-
prescriber result. Dispersion was measured independently for each general practitioner 
(GP) prescriber as the standard deviation of years in practice (i.e., years in practice was a 
time-varying measure).
6
 If the standard deviation (i.e., dispersion) was low, it suggested 
that the prescriber’s new statin patients were clustered within a short period of time 
during the study period. In contrast, higher standard deviation values (i.e., higher 
dispersion) suggested that new statin patients were dispersed across the study period. To 
illustrate the impact of dispersion on the modelling results for optimal adherence, we 
contrasted optimal adherence with the mean years in practice and the dispersion (or 





S-Table 3: Percentage of patients exhibiting optimal adherence (proportion of days 
covered >=80% of statin medications) by quartiles of prescriber’s years in practice, 
and standard deviation of years in practice.  
      Length of years in practice (quartiles) 
     <10.0 years 10.0 to 19.3 19.4 to 31.4 >31.4 Subtotal 
   Prescriber
s (n) 
395 386 389 392 1,562 






























































aAdherent patient = patients with a proportion of days covered >=80% of statin medications; bstandard deviation of years in practice 
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 Summary Chapter 5
5.1 Overview of key findings 
This research consisted of three separate studies examining the impact of 
physicians on the occurrence of optimal medication adherence in a Canadian health care 
setting.  Physicians are key participants in almost all aspects of prescription medication 
use in Canada and may influence adherence through several pathways connected to their 
professional role including diagnosing, counseling, prescribing, and follow-up.
1-8
  The 
impact of physicians on medication adherence is an important research area for several 
reasons. Models attempting to predict (or explain) medication adherence have performed 
very poorly in published studies.
9-11
 A study by Wong and colleagues tested a wide array 
of clinical factors and administrative data available for a cohort of 444,481 patients 
receiving oral blood-glucose-lowering medications but were only able to account for 2.9% 
of the variance in optimal adherence (i.e., adherence of at least 80%).
10
 Studies such as 
these generally have not included the multiple possible contributions of individual 
physician prescribers, and a comprehensive assessment of the physician impact on 
medication adherence had not been conducted previously.   
The first study (Chapter Two) examined the most commonly used measure 
representing continuity of care (COC) in population-based medication adherence 
studies.
12-15
 We found evidence that physicians with relatively low visit frequency may 
still be providing diverse services to their patients. Moreover, integrating diverse services 
into the COC definition resulted in higher discrimination and also improved prediction 




Our findings align with the concept of the ‘medical home’ where a single primary 
care team takes responsibility for “providing and arranging all the patient’s health care 
needs”.
16-18
  Although it cannot be concluded that our integrated approach to COC is 
perfect, it was a clear improvement over the traditional one-dimensional measure based 
exclusively on the number of physician visits. Our study suggests that clinical service and 
prescribing dimensions should be integrated into COC measure in population-based 
adherence models. 
The second study (Chapter Three) aimed to determine if age and sex concordance 
between physicians and patients influence optimal adherence to statin medications. We 
found no effect of age concordance but a possible association between sex-concordance 
and adherence could not be ruled out. Although it failed to reach statistical significance, a 
possible association could not be ruled out because of potential bias towards a null 
finding. Specifically, patients with a strong preference for a same-sex prescriber were 
likely over-represented in the sex-concordant group and under-represented in the 
discordant group.  Future research should explore the relevance of sex concordance in 
underserved/rural areas where access is limited to a single physician. The role of sex 
concordance is supported by a strong theoretical rationale. 
19-28
 
The third study (Chapter Four) aimed to explore the extent to which ‘prescriber 
effects’ may help explain variance in patient adherence to statin medications.  We further 
examined ‘prescriber effects’ as: a) a ‘latent’ effect (i.e., physician effect unexplained by 
patient and prescriber characteristics); and b) specific prescriber characteristics and their 
association with statin adherence. Overall, the physician impact on adherence was weak, 
only accounting for a small percentage of the overall variance between patients.  Further, 
physician characteristics contributed very little as most of their effect could not be 
124 
 
explained by measured factors.  The theoretical justification for investigating the overall 
impact of physicians on medication adherence was strong. Many papers reported 
significant associations between adherence and physician level skills such as 
communication and trust
22, 24, 29-32





 Our findings suggest that the association between physician factors and 
adherence observed in previous studies may be similar to reverse causality bias where 
adherent patients may have been more likely to rate their physician highly on factors such 
as communication while a non-adherent patient may rate the same physician poorly on 
these characteristics.  However, the findings of this study identified several important 
issues that need to be addressed in future studies, especially regarding physician 
remuneration types and their impact on medication adherence.    
5.2 Strengths and limitations 
Three population-based cohort studies were performed using validated 
administrative data. Thus the study population was highly generalizable to other 
Canadian health care settings.  In these studies, we used robust statistical models 
(including GEE and multi-level models) along with a comprehensive array of patient- or 
physician- related variables to minimize confounding. For example, in study three, 
patients were nested within prescribers and form a two-level structure. Apart from the 
individual level confounders (e.g., age, sex, health conditions, etc.) that are commonly 
considered for optimal patient adherence, other potential confounding effects must be 
addressed. For example, ecological effects may be important such as cross-level effect 
modification as well as indirect/direct cross level effects.
37
 We used multi-level models to 
address some of the possible ecological and cross-level confounding related to physicians; 
however, additional effects are possible.  
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Although the threshold to define optimal adherence (i.e., >=80%) is widely 
adopted,
38
 evidence remains insufficient to confirm its clinical relevance.  Recently, a 
study showed that optimal treatment effect (blood low-density lipoprotein <=1.8 mmol) 
can be achieve even though adherence to statin was as low as 50%.
39
 The ideal adherence 
threshold may also vary for different medications or different lengths of follow-up.
40
 A 
study showed that the cut-off for oral antidiabetic medications should be 90% to achieve 
target blood glucose level (Hemoglobin A1C <=7.0%).
41
 As such, it is important to 
examine the distribution of the adherence level, and perform sensitivity tests by applying 
different adherence cut-offs ranging from 50% to 100%, as we did in our studies. 
However, there were weaknesses to be considered. First, these studies were based 
on population of a public health care system in which patients can freely choose the care 
providers. Also, only statin medications were examined. Thus, generalizability of the 
findings to populations of other health care settings, or to other disease states such as 
mental health conditions cannot be assumed.  Second, while it was reasonable to choose 
the most frequent prescribers, we did not measure the impact of other physicians such as 
other GP prescribers, primary care providers (i.e., the most frequently visited physicians), 
or specialists. Third, there was a lack of clinical data (e.g., laboratory test results and 
electronic medical records), and measures on social economic factors (e.g., ethnicity, 
education level, and employment). These could have confounded the findings. Fourth, 
there were limited physician variables that can be captured in the available data. 
Additional information about physicians such as knowledge, personality, working attitude, 
and communication skills may have confounded the results. Future studies should attempt 
to identify additional data about prescribing physicians and their relationship with 
patients. Finally, lack of randomization in these studies limited our control over 
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unmeasured confounding. This limitation appeared to be especially problematic for 
assessments of remuneration type and country of medical training. Devlin and colleagues 
reported that physicians may self-select into a remuneration type due to uncaptured 
personal preference and characteristics.
42
 The effect of remuneration type and graduate 
country on medication adherence should be examined in future studies in order to 
improve our understanding of these factors.   
5.3 Future research 
The focus of this dissertation was the impact of physicians on the outcome of 
patient medication adherence.  Traditional approaches in adherence research often focus 
solely on patient-related factors, almost as if non-adherence is a pathologic condition.
43
  
Raising awareness about the role of health care providers and the health care system is 
important as we continue to understand this complex phenomenon. The search for 
answers to the root causes of medication adherence remains elusive at the population 
level.  However, continued research on this topic is crucial given the challenges facing 
health care sustainability in countries around the world. Medication adherence represents 
a prime target for improving care of chronic conditions and keeping people out of 
hospitals. The findings of this research can and should be extended.   
First, it is not clear whether our candidate medication class, statins, influenced the 
findings of this research. Different findings may have been observed if other classes were 
used. For example, perhaps sex concordance is important for some drugs but not others.  
It would be logical to investigate sex-specific conditions such as menopausal or 
andropausal treatments in a similar analysis. It is also possible that the overall physician 
effect is small for statins but larger for patients with mental health conditions where 
relationships and counseling may be more prominent.  
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Second, some of our findings may not be generalizable to all health care settings.  
Future studies should re-examine the impact of sex-concordance in areas where provider 
access is limited or in health systems that limit choice of providers. In addition, further 
studies might explore the impact of physician-reimbursement strategies (i.e., NFFS or 
FFS) using methods that will address the high risk for bias due to non-randomization (e.g., 
methods to randomize patients into FFS and NFFS physician groups with consent from 
patients, or to adopt a quasi-experimental design which allows patients to switch between 
FFS and NFFS physicians).  
Third, important potential confounders were not captured in administrative 
databases. These factors include perception of risk, communication style of provider, 
race/ethnicity concordance, patient-physician trust level, perceived medication 
complexity, and conflicting medication information. As such, efforts must continue to 
enable population-based researchers to access and link electronic medical records, 
behaviour-related data, and high-quality survey data in future studies.  
Finally, specific follow-up studies should be conducted.  For example, for the first 
study, the absolute number of visits to prescribers might further enhance the COC 
measure’s performance so it should be tested in future studies. Also integrated COC 
measure may still be improved upon by investigating other services and customizing for 
local health care settings. In study two, the effect of age concordance on adherence may 
be more important among individuals treated for psychiatric conditions such as 
depression.  Unlike statin users (who are usually at or above 40), patients suffering from 
mood disorders are of a wider age range, and are more likely to present age discordance.  
Our findings suggest that physicians play a relatively minor role in medication 
adherence of their patients.  However, many outstanding issues remain unexplored in this 
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area and medication adherence continues to be a critically important field of health 
research.  It is hoped that his research will help move the field towards the next important 
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